Clinical Trials

Clinical Trials Office

Code Clinical Trial Title Phase
SOLTI-150 3 (PROMETEO) Combination of Talimogene Laherparepvec with Atezolizumab in residual breast cancer following standard neoadjuvant multi-agent chemotherapy (PROMETEO TRIAL). 0
SOLTI-1802 ( ONAWA) A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women with Hormone Receptor-Positive and HER2-ne gative Breast Cancer. 0
1280.18 An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally
advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.
I
1315.2 An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combi nation with decitabine in patients with acute myeloid leukemia I
1336-0011 An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability,
pharmacokinetics, pharmac odynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
I
1401-0001 An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administer ed intravenously in patients with advanced solid tumours. I
1412-0001 A first-in-human phase Ia/b, open label, multicentre, dose escalation study of BI 905711 in patients with advanced gastrointestinal cancers. I
1426-0001 Phase I, first in human trial evaluating BI 1387446 alone and in combination with BI 754091 in solid tumors. I
17-BI-1206-02 Ensayo clínico de fase I/IIa de BI-1206, un anticuerpo monoclonal contra CD32b
(Fc γ RIIB), en combinación con rituximab en personas con linfoma n o hodgkiniano
de linfocitos B de escasa malignidad que ha recidivado o es resistente al rituximab
I
20140318 A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318). I
20180290 A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 i n Subjects with MUC17-Positive Gastric and Gastroesophageal Junction Cancer. I
2018-523-00 US1 A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma. I
201973 A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer. I
204686 "A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors" I
204691( ICOS ) A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects
with Selected Advanced Solid Tumors.
I
204697 A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GS K525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC). I
207675 A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3368715 in pa rticipants with solid tumors and DLBCL. I
208471 A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Spec ific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer. I
2102-ONC-10 2 A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation. I
2SMALL Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Pr ogressed Following Prior Therapy with Platinum-Based Chemotherapy. I
4010-01-001 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors I
5225101 (GA TTO) "A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients with EGFR-Positive Metastatic Solid Tumors" I
56021927PCR 2032 (KRONOS) An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Meta static Castration-esistant Prostate Cancer. I
61186372EDI 1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanc ed Non-Small Cell Lung Cancer. I
63709178AM L1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects with Relapsed or Refr actory AML. I
63723283LUC 1001 A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, a n Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers. I
64091742PCR 2002 A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer. I
64619178EDI 1001 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Argini ne Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
67571244AM L1001 A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractor y Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). I
67856633LY M1001 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Part icipants With NHL and CLL I
73841937NSC 2001 A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients wit h EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC). I
8374-CL-0101 A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
A206T-G01-0 01 (PROTER) A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177 Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic
treatment.
I
ACT15320 A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cance r therapies in participants with lymphoma I
ACT15377 Estudio en fase 1/2, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de isatuximab (SAR650984) en combinació n con atezolizumab o solo isatuximab en pacientes con enfermedades malignas avanzadas I
AFM24-101 A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with A dvanced Solid Cancers. I
AG270-C-001 A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP. I
AMC303-01 "A safety, tolerability and pharmacokinetic dose escalation and expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin?" I
ARMY-1 First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia I
ARRAY-162-2 02 An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previou sly Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation I
ARTFORCE Cisplatin concomitant with standard or adaptive high dose radiotherapy for advanced head and neck cancer. I
AUTO4-TL1 A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMEN T TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR
REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA.
I
B7461001 PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HAR BORING SPECIFIC MOLECULAR ALTERATIONS. I
B9991005 A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMA B (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. I
B9991023 A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHE MOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES. I
B9991032 A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS. I
BAY 1163877 / 19131 An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ine ligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. I
BAY 1163877 /19774 (ROCOCO) A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose (RP2D)of the combination of roga ratinib and copanlisib in patients with FGFR-positive refractory, locally advanced or metastatic solid tumors. I
BAY88-8223/ 19781 An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer. I
BAY94-9343/ 15834 Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies. I
BGB-290-103 A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors. I
BGB-A317/B GB-290 A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety,
Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in Combination with the PARP Inhibitor BGB-290 in Subjects with Advanced Solid Tumors.
I
BLU-285-1101 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors. I
BLU-554-1101 A Phase 1 Study to Assess the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepato cellular Carcinoma and Cholangiocarcinoma
I
BLU-667-1101 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanc ed Solid Tumors. I
BO39610 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERA PY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MORPHEUS-LUNG). I
BO40933 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB IN COMBINATION WITH RUCAPARIB IN PATI ENTS WITH ADVANCED BREAST, OVARIAN, OR PROSTATE CANCER. I
BP39365 AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, DOSE-ESCALATION, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6874281, IN COMBINATION WITH ATEZOLIZUMAB ±
BEVACIZUMAB, FOLLOWING OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH UNRESECTABLE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.
I
BP40087 AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMO R ACTIVITY OF RO7122290, A FIBROBLAST ACTIVATION
PROTEIN-a (FAP) TARGETED 4-1BB LIGAND (CD137L), WITH OR WITHOUT OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB FOLLOWED BY TUMOR SPECIFIC EXPANSION COHORT(S).
I
BP40234 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF I NTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
BP40657 A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTA NEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. I
BP41054 AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSIS TING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED AND/OR METASTATIC MELANOMA. I
BP41072 AN OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7227166 (A CD19 T ARGETED 4-1BB LIGAND) IN COMBINATION WITH BINUTUZUMAB AND IN COMBINATION WITH RO7082859 (CD20-TCB) FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S
LYMPHOMA.
I
BREPEM-LH-2 2017 "A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantr one (BrEPEM) for Older Patients with Untreated Hodgkin Lymphoma (HL)". I
Brigatinib-10 01 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid T umors. I
C0541001 A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS. I
C2321001 A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTOR Y SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL). I
CA001044 A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Ca ncer I
CA011-001 A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combi nation with Nivolumab in Subjects with Selected Advanced Solid Tumors or Hematologic Mallignancies. I
CA017-003-II A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malign ant Tumors. I
CA022-001 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. I
CA209-358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negat ive Solid Tumors. I
CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H). I
CA223-001 "A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors" I
CA224-020 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558) in Advanced Solid Tumors I
CADPT01A12 101C A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer. I
CB103-C-101 A PHASE I/IIA, MULTI-CENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY WITH EXPANSION ARMS TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKI NETICS AND PRELIMINARY EFFICACY OF CB-103 ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL ALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY . I
CC-122-DLBCL -002 A Phase 1/2 Open-label, Multicenter Study of CC-122 in Combination With R-CHOP-21 for Previously Untreated Poor-Risk (IPI ≥ 3) Diffuse Large B-Cell Lymphoma I
CC-122-ST-00 1 Estudio de fase 1a/1b multicéntrico, abierto, de búsqueda de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia preliminar del modificador de la ruta pleiotrópica, CC-122, administrado por vía oral a sujetos con tumores sólidos avanzados, linfoma no Hodgkin o mieloma múltiple I
CC-220-MM-0 01 A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND T OLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA I
CC-90002-ST- 001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-90002, A MONOCLONAL ANTIBODY DIRECTED AGAINST CD47, IN SUBJECTS WITH ADVANCED S OLID AND HEMATOLOGIC CANCERS I
CC-90010-ST- 001 A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-9001 0 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY NON-HODGKIN?S LYMPHOMAS I
CC-90011-SCL C-001 A PHASE 1B, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-90011 GIV EN IN COMBINATION WITH CISPLATIN AND ETOPOSIDE TO SUBJECTS WITH FIRST LINE, EXTENSIVE STAGE SMALL CELL LUNG CANCER. I
CC-90011-ST- 001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-9001 1 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN’S LYMPHOMAS. I
CC-99282-CLL -001 A PHASE 1B, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-99282 IN COM BINATION WITH OBINUTUZUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. I
CC-99282-NH L-001 A PHASE I, MULTI-CENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND
PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY NONHODGKIN LYMPHOMAS (R/R NHL)
I
CDRB436C22 01-MEK116833 An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical
Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in
Combination in Subjects with BRAF-mutation V600E or V600K Positive Colorectal Cancer.
I
CFAZ053X210 1 A phase I, open-label, multi-center dose escalation study of FAZ053 as single agent and in combination with PDR001 in
adult patients with advanced malignancies.
I
CGWN323X2 101 A Phase I/Ib open-label, multi-center, dose escalation study of GWN323 (anti-GITR) as a single agent and in combination with PDR001 (anti-PD-1) in p atients with advanced solid tumors and lymphomas I
CHDM201X21 01 A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and
hematological tumors characteriz ed by wild-type TP53 .
I
CHDM201X21 03C A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma I
CIDH305X210 1 A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations. I
CINC280X210 5C A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR
mutated non-small cell lung cancer
I
CJBH492A121 01 A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and No n-Hodgkin’s Lymphoma (NHL). I
CKAZ954A12 101 A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors. I
CLAG525X210 1C A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patient s with advanced malignancies I
CLAG525X210 1C-II A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patient s with advanced malignancies. I
CLDK378A212 0C A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic ly mphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) I
CLEE011X210 6 A phase Ib/II trial of LEE011 in combination with everolimus (RADO001) and exemestane in the treatment of postmenopausal women with estrogen r eceptor positive, Her2 negative locally advanced or metastatic breast cancer. I
CLGK974X210 1 A Phase I, open-label, dose escalation study of oral LGK974 in patients with melanoma and breast cancer. I
CLHC165X210 1 A Phase I/Ib, open-label, multi-center dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 in patients with advanced malignancies. I
CLXH254X210 1 A phase I dose finding study of oral LXH254 in adult patients with advanced solid tumors harboring MAPK pathway alterations. I
CLXH254X210 2 A Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or
metastatic KRAS or BRAF mutant N on-Small Cell Lung Cancer or NRAS mutant melanoma.
I
CMBG453D12 101 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis. I
CNIR178X220 1 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin ly mphoma. I
CNIZ985B121 01 A Phase I/Ib Study of Subcutaneous Recombinant NIZ985 ((het-IL-15) (IL-15/sIL-15Rα)) in combination with Spartalizumab in adults with check point i nhibitor (CPI) relapsed advanced malignancies. I
CNTO1959CO R1001 A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the
Efficacy of Guselkumab in Subjects with Familial Adenomato us Polyposis.
I
CO40115 "A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERA PY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MORPHEUS TNBC)" I
CO40939 A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WI TH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
CO41012 AA PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMON E RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER. I
CPDR001C21 01 Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1unselected, metastatic NSCLC patien ts I
CPDR001X21 01-II Estudio de fase I/II, abierto, multicéntrico, de la eficacia y la seguridad de PDR001 administrado en pacientes con tumores malignos avanzados. I
CPDR001X21 02 Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001
in combination with LCL161, e verolimus (RAD001) or panobinostat (LBH589) .
I
CP-MGA012- 01 A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors. I
CP-MGD013- 01 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unrese ctable or Metastatic Neoplasms. I
CTMT212X21 06 A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid t umors. I
CTNO155B12 101 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155
in combination with spartalizum ab or ribociclib in selected malignancies.
I
CTNO155X21 01 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors I
CV-8102-008 Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the hea d and neck, or adenoid cystic carcinoma. I
D081EC00001 EEstudio en fase I, abierto, de 2 partes, multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia de olaparib en combinación con carboplatino; Parte A: aumento escalonado de la dosis de olaparib en combinación con carboplatino en pacientes con cáncer de mama avanzado HER-2 negativo; seguida de Parte B: fase de expansión de olaparib en combinación con carboplatino para el tratamiento neoadyuvante de pacientes con cáncer de mama avanzado HER-2 negativo que presentan mutaciones BRCA1/2 en la línea germinal. I
D2615C00001 (BISCAY) An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Canc er (MIBC) who have progressed on prior treatment (BISCAY) I
D4190C00010 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody)in Subjects with Advanced Solid Tum ors I
D419NC00001 A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors. I
D7980C00001 (MEDI5752) A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics
Immunogenicity, and Antitu mor Activity of MEDI5752 in Subjects with Advanced Solid Tumors.
I
D8530C00001 A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Adv anced Breast CancerA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer. I
Debio 1143-1 06 SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose -optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. I
DEBIO 1347-1 01 A phase I, gene alteration-based, open label, multicenter study of oral Debio1347 (CH5183284) in patients with advanced solid malignancies, whose t umours have an alteration of the FGFR 1, 2 or 3 genes. I
DEBIO1347-2 01 Ensayo "basket" de fase II del paninhibidor del FGFR selectivo por vía oral Debio 1347 en pacientes con tumores sólidos que presentan una fusión de FGFR1, FGFR2 o FGFR3 I
DU176b-A-U1 57 A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NONRANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS I
EMR200647-0 01 (TRAP001) Ensayo de fase I, abierto, con dosis múltiples ascendentes, para investigar la seguridad, tolerabilidad, farmacocinética, y actividad biológica y clínica d e MSB0011359C en sujetos con tumores sólidos metastásicos o localmente avanzados y expansión a indicaciones seleccionadas I
EOGBM1-18 A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Poi nt Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma (Rosalie study). I
GCT1021-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab ved otin, HuMax®-AXL-ADC) in patients with solid tumors. I
GCT1029-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors. I
GCT1044-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumours. I
GCT1046-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects
with malignant solid tumors.
I
GCT3009-01 “Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A Firstin-Human, Open-label, Phas e I/IIa Dose Escalation Trial with Dose Expansion Cohorts” I
GCT3013-01 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma I
GEIS 58 (OLA TRASTS) "Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado" I
GO29781 “An open-label, multicenter, phase I/Ib trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and comb ined with atezolizumab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia” I
GO29834 A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDO MIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR I
GO30103 (FEL IX) "A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBI NATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS" I
GO39374 A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF GDC-0077 AS A SINGLE AG ENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER
I
GO39733 A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBIN ATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
GO39932 "A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 9545 Al one or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer" I
GO40554 A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLO WING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN
PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE UNABLE TO TOLERATE FULL-DOSE CHEMOTHERAPY.
I
GO40800 "A PHASE IB/II STUDY EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIE NTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY AND EFFICACY OF IDASANUTLIN IN THE MAINTENANCE OF FIRST AML COMPLETE REMISSION " I
GO40987 A PHASE I, MULTICENTER, OPEN-LABEL PREOPERATIVE SHORT-TERM WINDOW STUDY OF GDC-9545 IN POSTMENOPAUSAL WOMEN WITH STAGE I-III OPERABLE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER. I
GS-US-352-43 65 Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelo fibrosis (Post-PV/ET MF) I
H3B-6527-G0 00-101 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced H epatocellular Carcinoma I
H9H-MC-JBA H Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination with Lomustine in Patients with Recurrent Malignant Glioma I
H9H-MC-JBEF Protocol H9H-MC-JBEF(a) A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming G rowth Factor–? Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti–PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non–Small Cell Lung Cancer, Hepatocellular Carcinoma,or Glioblastoma (Phase 2) I
I5B-MC-JGDL A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Tr eatment of Advanced Soft Tissue Sarcoma I
I5B-MC-JGDP A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in t he Treatment of First-Line Metastatic Pancreatic Cancer I
I6F-MC-JJCD A Phase 1b Study of LY3039478 in Combination with Other Anticancer Agents in Patients with
Advanced or Metastatic Solid Tumors.
I
I8X-MC-JECA A Phase 1 Study of LY3200882 in Patients with Solid Tumors. I
ICO-VCN-H& N-2018 A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck. I
IMC-C103C-1 01 A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-po sitive Patients with Advanced MAGE-A4-positive Cancer. I
IMGN853-040 2 A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in
Combination with Bevaciz umab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.
I
INCAGN 1876 -201 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies. I
INCB 01158-1 01 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Si ngle Agent and in Combination with Immune Checkpoint Therapy in Patients with vanced/Metastatic Solid Tumors. I
INCB 50465-1 12 A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ib rutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) I
INCB 54828-2 07 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Local ly Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). I
INCB 59872-1 03 An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refracto ry Ewing Sarcoma. I
INCB01158-2 06 A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Parti cipants With Relapsed or Refractory Multiple Myeloma. I
INCMGA0012 -203 A Phase 2 Study of INCMGA00012 (PD-1 inhibitor) in Participants With Selected Solid Tumors (PODIUM-203). I
IO102-012(K N-764) An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chem otherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer. I
IOV-COM-202 A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors. I
J1F-MC-JZFA A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors. I
J2J-MC-JZLA A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer. I
KO-ERK-001 Un primer ensayo en humanos de fase I de KO-947 en malignidades no hematológicas localmente avanzadas, no reseccionableso metastásicas,
recidi vantes y/o refractarias
I
KO-TIP-001 An Open Label Phase II Study of Tipifarnib in Advanced NonHematological Malignancies with HRAS Mutations I
LOXO-EXT-17 005 A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion
Cancers.
I
LOXO-RET-17 001 "A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medularry Thyroi d Cancer, and Other Tunors with Increased RET Activity". I
LOXO-RET-18 037 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged Dur ing Transfection (RET) Activation (LIBRETTO-201). I
LOXO-TRK-15 002 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors I
M19-037 A Phase 1, Multi-Center, Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Pharmacokinetics of ABBV-927 and ABBV-368 w ith and without ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumor. I
MCLA128-CL- 01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors I
MCLA-158-CL 01 Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumo rs. I
MEN1309-01 OPEN-LABEL, MULTICENTER, PHASE I DOSE ESCALATION STUDY OF MEN1309, A CD205 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH CD205-POSI TIVE METASTATIC SOLID TUMORS AND NON-HODGKIN LYMPHOMA. I
MEN1611-01( B PRECISE 01) OPEN-LABEL, MULTICENTER, PHASE IB DOSE-ESCALATION STUDY OF MEN1611, A PI3K INHIBITOR COMBINED WITH TRASTUZUMAB ± FULVESTRANT, I N SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADVANCED) OR METASTATIC (A/M) BREAST CANCER PROGRESSED TO ANTI-HER2 BASED THERAPY . I
MO29518 AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMORS I
MS100036-00 20 A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, s afety, tolerability, and pharmacokinetics of the DNA-PK inhibitor M3814 in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer. I
MSC-1-101 “A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immu nogenicity and Antitumor Activity of MSC-1 in Patients with Advanced Solid Tumors. I
NP30179 A MULTICENTER, OPEN-LABEL, PHASE I STUDYTO EVALUATE THE SAFETY, EFFICACY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF OBINUTUZUMAB (GAZYVA/GAZYVARO) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA I
NP39488 AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) I N ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA I
NP40126 A PHASE 1B STUDY EVALUATING RO7082859 IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBI CIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH RELAPSED REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) OR IN PARTICIPANTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA I
NP40435 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINAR Y ANTI TUMOR ACTIVITY OF RO7121661, A PD-1/TIM-3 BISPECIFIC NTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
NP41300 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMI CS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
PCI-32765LY M1002 A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivo lumab in Subjects With Hematologic Malignancies I
PCYC-1128-C A A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors I
Pevonedistat- 1016 “A Phase 1/1b Study of Pevonedistat in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonoc ytic Leukemia, or Acute Myelogenous Leukemia With Severe Renal Impairment or Mild Hepatic Impairment” I
PM14-A-001- 17 Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumor s I
PRN1371-001 A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with
Advanced Solid Tumors, foll owed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations
I
PUMA NER-5 201 An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal
Growth Factor Receptor (EGFR, HER2, HER3 ) Mutations or EGFR gene amplification.
I
P-VCNA-001 A phase I, multicenter, open-label, dose escalation study of intravenous administration of VCN-01 oncolytic adenovirus with or without gemcitabine and Abraxane® in patients with advanced solid tumors. I
R1979-ONC-1 504 A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, AND REGN2 810, AN ANTI-PROGRAMMED DEATH-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH B-CELL MALIGNANCIES I
R2810-ONC-1 423 (REGENERON) A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death – 1
(PD-1), as Single Therapy a nd in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies
I
REALIB-LLA-2 017 Ensayo en fase I-II, sin enmascaramiento y no aleatorizado, para evaluar el papel de Idelalisib en pacientes con leucemia linfoblástica aguda (LLA) en r ecaída o refractarios a otros tratamientos, y en pacientes ancianos con LLA en los que se desaconseja el uso de terapias convencionales I
RXDX-101-02 (STARTRK-2) "An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tum ors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements" I
SC103 A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pem brolizumab in patients with selected advanced/metastatic solid tumors. I
SGN228-001 A phase 1 study of SGN-CD228A in subjects with select advanced solid tumors. I
SGN47M-001 A phase 1 study of SGN-CD47M in patients with advanced
solid tumors.
I
SGNTV-001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. I
SL01-DEL-101 Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with A dvanced Solid Tumors or Lymphomas. I
SRA737-02 Ensayo en fase I/II de SRA737 (un inhibidor de Chk1) administrado por vía oral en combinación con gemcitabina más cisplatino o gemcitabina únicam ente en pacientes con cáncer avanzado. I
SYM015-01 Ensayo de fase 1a/2a, abierto y multicéntrico, para investigar la seguridad, tolerabilidad y actividad antitumoral de dosis repetidas de Sym015, una m ezcla de anticuerpos monoclonales dirigida frente al receptor MET, en pacientes con tumores malignos sólidos en fase avanzada I
TCD14678 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination
with cemiplimab in adult patients with advanced solid tumors.
I
TED13751 A first-in-human study for the evaluation of the safety, pharmacokinetics and antitumor activity of SAR408701 in patients with advanced solid tumor s. I
TPU-TAS-120- 101 A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECE PTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR MULTIPLE MYELOMA WITH FGF/FGFR-RELATED ABNORMALITIES I
TRASTS-I (GEI S 37) Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos I
U31402-A-U1 02 A MULTICENTER, OPEN-LABEL PHASE 1 STUDY OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE NON-SMALL CELL LUNG CANCER.
I
VHIO17002 ( MO39164) Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanc ed Solid Tumours. I
VHIO-PBF-99 9-01 "Phase I/Ib trial of single agent PBF-999 in solid tumour advanced cancer" I
W00101 IV 1 01 Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advan ced or metastatic solid tumors International, multicenter, open label study. I
WIN001 (SPRI NG) Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination. I
WO39409 "A phase Ib combination study of rucaparib (CO-338) and atezolizumab (MPDL3280A) in patients with advanced gynecologic cancers and triple-negati ve breast cancer" I
WO39608 (M ORPHEO 1) A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAP Y-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER). I
WO39613 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAP Y-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC). I
WP29945 AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAP EUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS. I
WP41188 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINAR Y ANTI TUMOR ACTIVITY OF RO7296682, A CD25-TARGETING, T-REGULATORY CELL DEPLETING ANTIBODY IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS I
WP41377 A FIRST IN HUMAN, OPEN LABEL, DOSE ESCALATION PHASE I STUDY EVALUATING SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIM INARY ACTIVITY PROFILE OF SINGLE AGENT RO7119929 (TLR7 AGONIST 4 ASIP) ADMINISTERED ORALLY TO PARTICIPANTS WITH UNRESECTABLE ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA, BILIARY TRACT CANCER, OR SOLID TUMORS WITH PREDOMINANTLY HEPATIC METASTASES. I
X16082 Ensayo de fase Ib/II para evaluar la eficacia y seguridad de ixazomib oral en combinación con sirólimus y tacrólimus como profilaxis de la enfermedad injerto contra huésped crónica. I
XL184-021 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Met astatic Solid Tumors. I
XL184-021 (P ULMON) A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Met astatic Solid Tumors. I
YO39609 "A phase Ib/II, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment c ombinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (morpheus-gastric cancer) " I
YO40482 A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH AD VANCED PLATINUM-SENSITIVE OVARIAN CANCER. I
ZEN003694-0 04 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer. I
MS201922-00 01 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combinati on With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors. I
42756493CA N2002/ODIN (RAGNAR) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations. I
208850 (STIN G) A Phase I First Time in Human Open Label Study of GSK3745417 administered with and without Anticancer Agents in Participants with Advanced Soli d Tumors. I
B9991040 (JA VELIN IL-2 Medley) Phase 1b/2 clinical trial in patients locally recurrent (not amenable to curative intent) or metastatic SCCHN or metastatic castration-resistant prostate cancer (mCRPC), I
KRT-232-104 "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Pa tients with Acute Myeloid Leukemia (AML)" I
SOLTI-1507 (I PATHER) A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PI3KCA-mutant, HER2-positive l ocally advanced or metastatic breast cancer (IPATHER) I
2455-002 An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma. I
EOADR1-19 ( SPENCER) A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma. I
GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS
OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH
TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS.
I
CO41942 ESTUDIO DE FASE IB, SIN ENMASCARAMIENTO, MULTICÉNTRICO, NO ALEATORIZADO, PARA EVALUAR LA SEGURIDAD, LA FARMACOCINÉTICA Y LA EFI CACIA DE MOSUNETUZUMAB EN COMBINACIÓN CON LENALIDOMIDA, O RO7082859 EN COMBINACIÓN CON LENALIDOMIDA, O RO7082859 EN COMBINACIÓN CON OBINUTUZUMAB MÁS LENALIDOMIDA EN PACIENTES CON LINFOMA FOLICULAR RESISTENTE O RECIDIVANT I
CO41863 A PHASE Ib/II, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFF ICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTANSINE (T-DM1) IN PREVIOUSLY TREATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS. I
CC-90010-GB M-002 A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90010 IN COMBINATION WITH TEMOZOLOMIDE
WITH OR WITHOUT RADIATION THERAPY IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.
I
CC-90011-ST- 002 A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with adva nced cancers. I
BP41628 AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSEESCALATION AND EXTENSION, PHASE IA/IB STUDY TO
EVALUATE SAFETY AND ANTI-TUMOR ACTI VITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
I
BNT411-01 Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics,
pharmacodynamics, and pr eliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer
(ES-SCLC).
I
CO41792 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF IPATASERTIB IN COMBINATION WI TH ATEZOLIZUMAB AND DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. I
ODO-TE-S101 An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food,Itraconazole,and Rifampinon Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors. I
1438-0001 A First–in-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3. I
M19-611 A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressi ng, Recurrent Non-Small Cell Lung Cancer. I
4020-01-001 ( AMBER) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AM BER). I
WP42004 "ESTUDIO DE FASE I, MULTICÉNTRICO Y ABIERTO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA Y FARMACODINÁMICA DE RO7 283420 EN MONOTERAPIA EN LEUCEMIA MIELOIDE AGUDA EN RECAÍDA/RESISTENTE HEMATOLÓGICA Y MOLECULAR" I
ICT01-101 A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and i n combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study). I
1381.2 An open label, Phase I dose-finding study of BI 754111 in combination with BI 754091 in patients with advanced solid
cancers followed by expansion cohorts at the selected dose of the combination in patients with non-small cell lung cancer and other solid tumors.
I
DCC-3014-01- 001 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with A dvanced Tumors. I
D6770C00001 Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Olecluma b in Advanced Solid Tumors. I
DEBIO 1143-1 06-II SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose -optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. I
70218902EDI 1001 A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors. I
Debio 0123-1 01 A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors. I
20180292 A Global Phase 1 Study Evaluating the Safety,Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 i n Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. I
CBLZ945X210 1 A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients wit h advanced solid tumors. I
MEN1611-02 (C-PRECISE-01) OPEN-LABEL,MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CAMUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING REGIMENS. I
CA011-001(H EMATOLOGIA) A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combi nation with Nivolumab in Subjects with Selected Advanced Solid Tumors or Hematologic Malignancies I
V937-013 Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Met astatic Solid Tumors. I
GO41751 A PHASE I, OPEN-LABEL, DOSE-ESCALATION PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER. I
CYTB323A121 01 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL. I
CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers . I
SGNTGT-001 A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies. I
73841937NSC 1001 An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monothe rapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer. I
213152 A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer with Disease Progression or Recurrence Following Treatment with a Platinun agent. I
CADPT01C12 101 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or met astatic BRAF V600 colorectal cancer. I
TAS-120-202 A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations. I
BP42169 AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7293 583, A TYRP1-TARGETING CD3 T-CELL ENGAGER, IN PARTICIPANTS WITH METASTATIC MELANOMA. I
DZB-CS-202 ( BASILEA) Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-neg ative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03). I
SGNB6A-001 A Phase 1 Study of SGN-B6A in Advanced Solid Tumors. I
MS200647_0 046 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer. I
FS222-19101 (F-STAR) A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects with Advanced Malignancies. I
1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated a dministration in patients with clinical benefit. I
MK-7339-002 A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homolog ous Recombination Deficiency (HRD) Positive Advanced Cancer. I
NBTXR3-102 ESTUDIO DE FASE I DE AUMENTO ESCALONADO/AMPLIACIÓN DE LA DOSIS DE NBTXR3 ACTIVADO MEDIANTE RADIOTERAPIA DE INTENSIDAD MODUL ADA EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS LOCALMENTE AVANZADO EN LA CAVIDAD BUCAL O LA OROFARINGE. I
MK-3475-555 (KEYNOTE-555) A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intraven ous Infusion in Participants with Advanced Melanoma (KEYNOTE-555). I
64619178EDI 1001-H A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Argini ne Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
207497 (DRE AMM6) A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GS K2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – (DREAMM 6) I
MM-398-07-0 2-03 A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patien ts with Previously Untreated, Metastatic Pancreatic Adenocarcinoma. I
MK-4280-001 "A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors" I
MK-3475-158 Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 15 8) I
3475-028 Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors. I
010463QM (A BACUS) A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder (ABACUS). II
010580QM (C ALYPSO) MEDI4736 combinations in metastatic renal cell carcinoma (CALYPSO) II
1280.4-II A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer II
1280-0022 Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in
combination with everoli mus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease.
II
1612-MG(EO RTC) Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immedia te combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation : an EORTC randomized phase II study (EBIN). II
1613-LCG (AP PLE) APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. II
1740-HNCG RANDOMIZED PHASE II STUDY OF CISPLATIN PLUS RADIOTHERAPY VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT DURVALU MAB VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT TREMELIMUMAB AND DURVALUMAB IN INTERMEDIATE RISK HPV-POSITIVE LOCOREGIONALLY ADVANCED OROPHARYNGEAL SQUAMOUS CELL CANCER (LA-OSCC). II
205801 (ENTR EE LUNG) A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC P articipants. II
2102-HEM-10 1 A Phase 1/2, Multicenter, Open-label study of FT 2102 as a single agent and in combination with Azacitidine or Cytarabine in patiens with Acute Myel oid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation II
2215-CL-0201 A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacit idine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy II
54767414M MY2040 A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens. II
64091742PCR 2001 (GALAHAD) A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies II
74494550AM L2001 A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Ch emotherapy. II
ABI-007-NSCL -006 A PHASE 2, RANDOMIZED, OPEN-LABEL,MULTICENTER STUDY TO ASSESS SAFETY AND EFFICACY OF NAB®-PACLITAXEL (ABI-007) WITH EPIGENETIC M ODIFYING THERAPY OF CC-486, AND NAB®-PACLITAXEL MONOTHERAPY AS SECOND-LINE TREATMENT IN SUBJECTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): ABOUND.2L. II
ABT-C5-2016 (ABILITY) A phase I/II open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced e ndometrial cancer or squamous NSCLC. II
ADCT-301-20 1 “A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refr actory Hodgkin Lymphoma” II
ADP-0044-00 2 (SPEARHEAD) A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposa rcoma. II
AP32788-15- 101 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lun g Cancer. II
APR-407 (PIS ARRO) PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemo therapy With or Without APR-246 II
APX005M-00 2 A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma. II
APX005M-01 0 A Phase II Multicenter, Open-label Study in Two Parallel-Groups to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M in Adult s with Immunotherapy Naive Unresectable or Metastatic Melanoma. II
ARRAY-162-2 02-II An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previou sly Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation. II
ARRAY-818-2 02 A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer. II
AXI-IIG-02 A PHASE II RANDOMIZED DOUBLE-BLIND STUDY OF SANTOSTATIN LAR IN COMBINATION WITH AXITINIB VERSUS PLACEBO IN PATIENTS WITH PROGR ESSIVE ADVANCED WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMAS OF NON-PANCREATIC ORIGIN (CARCINOIDS) II
AZA-MDS-003 (aza oral) A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Plac ebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes II
B7461001-II PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HAR BORING SPECIFIC MOLECULAR ALTERATIONS. II
B9991001 "A phase 3, mulitcenter, multinacional, randomized, open-label, parallel-arm study of Avelumab* (MSB0010718C) plus best supportive care versus be st supportive care alone as a maintenance treatment in patients wirh locally advanced or metastatic urothelial cancer whose disease did not progress after coppletion of first-line platinum-containing chemotherapy". II
BARBICAN BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant hemotherapy plus atezolizumab in women with triple-negative breast cancer. II
BGB-290-202 (PAMAPARIB) A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer ( mCRPC) with Homologous Recombination Deficiency (HRD). II
BGB-A317-20 8 A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 i n Patients with Previously Treated Hepatocellular Unresectable Carcinoma. II
BGBC008 A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the L ungA Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with
Previously Treated Advanced Adenocarcinoma of the Lung.
II
BL-8040.PAC. 201 (COMBAT) A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF BL-8040 AND PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC PANCREATIC CANCER, THE COMBAT STUDY. II
BO29554 (BF AST) A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED
THERAPIES AS TREATMENTS FOR PATIENTS WIT H ADVANCED OR METASTATIC NON−SMALL CELL LUNG
CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST
ASSAY SCREENING TRIAL).
II
BST-LT-01 Ensayo clínico fase Ib-II, prospectivo, multicéntrico, abierto y no controlado para evaluar la seguridad y eficacia inmunológica de la infusión de linfocit os T específicos frente a virus a partir del mejor donante disponible en receptores de un trasplante alogénico de progenitores hematopoyéticos II
C-144-01 A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma. II
C-145-04 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurren t, Metastatic or Persistent Cervical Carcinoma. II
C31004 A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer. II
C31006 (TAKE DA) An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanc ed or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor herapy. II
C-700-01 A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics,
Biological, and Clinical Activity of A GEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, with
Expansion to Second Line Cervical Cancer.
II
CA209-171 Ensayo clínico abierto y multicéntrico de nivolumab (BMS-936558) en monoterapia en sujetos con cáncer de pulmón no microcítico (CPNM) epidermo ide avanzado o metastásico que han recibido al menos dos líneas de tratamiento sistémico previas para el tratamiento del CPNM epidermoide en estadio IIIb/IV II
CA209-275 Ensayo clínico Fase II, de brazo único, de nivolumab (BMS-936558) en sujetos con cáncer urotelial metastásico o irresecable que han progresado o rec idivado tras tratamiento con un agente derivado del platino. II
CA209-548 A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult S ubjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma. II
CA209-648 A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated sophageal Squamous Cell Carcinoma. II
CA209-7A8 “Randomized, Non-comparative Neoadjuvant Phase II Study in Postmenopausal Women with Stage II-III, ER+/HER2- Breast Cancer with Safety Run-in , Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7A8)”. II
CA209-9HX (P ROSTRATEGY) PROSTRATEGY: A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer. II
CA209-9X8 An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Met astatic Colorectal Cancer. II
CA224-047 A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated M etastatic or Unresectable Melanoma. II
CBGJ398X220 4 A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy. II
CBYL719X240 2 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of
alpelisib plus fulvestrant or letrozole in pat ients with
PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
II
CCTL019A220 5B Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy. II
CEGF816X210 1-II A phase I/II, multicenter, open-label study of EGFRmut–TKI EGF816 administered orally in adult patients with EGFRmut
solid malignancies.
II
CEGF816X220 1C Estudio de fase II, multicéntrico, abierto de EGF816 en combinación con nivolumab en pacientes adultos con cáncer de pulmón de células no pequeña s con mutación del EGFR y de INC280 en combinación con nivolumab en pacientes adultos con cáncer de pulmón de células no pequeñas con cMet positivo. II
CETB115J241 1 A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refra ctory or relapsed after first-line steroids (TAPER) II
CINC280A220 1 Estudio de fase II, multicéntrico, de tres cohortes con el inhibidor oral de cMET, INC280, en pacientes adultos con cáncer de pulmón de células no peq ueñas (NSCLC) avanzado y EGFR wild type (wt), que han recibido una o dos líneas previas de terapia sistémica para enfermedad avanzada/metastásico. II
CINC280X210 5C-II A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR
mutated non-small cell lung cancer
II
CL03-ORY-10 01 SCLC (CLEPSIDRA) A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer. II
CLBH589D22 22 Estudio de Fase 2, multicéntrico, aleatorizado y abierto, que evalúa la seguridad y eficacia de tres regímenes diferentes de panobinostat en combinaci ón con bortezomib subcutáneo y dexametasona oral en pacientes con mieloma múltiple ecidivante o recidivante/refractario que hayan sido previamente expuestos a agentes inmunomoduladores. II
CLGX818X210 9 (LOGIC2) Estudio fase II, multicéntrico, abierto de LGX818/MEK162 en combinación seguido de una combinación razonable
con agentes diana después de la pr ogresión, para superar la resistencia en pacientes adultos con melanoma metastásico o localmente avanzado con mutación BRAF V600.
II
CLR_15_03 “A Two-part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in He althy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)” II
CO-338-017(A RIEL-2) Ensayo abierto de fase II de rucaparib en pacientes con carcinoma epitelial de ovario, carcinoma de trompa de Falopio o carcinoma primario de perito neo, de alto grado, recidivado y sensible al platino II
CORT125134- 552 (CORT) A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant O varian, Fallopian Tube, or Primary Peritoneal Cancer. II
CX-839- (CAN TATA) A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cab ozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC). II
D5161C00003 (ELIOS) "A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treate d with osimertinib". II
D5336C00001 (VIOLETTE) A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination wit h Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE). II
D5660C00004 A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. II
D6070C00005 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447)
with or without Durvalumab in Combina tion with Chemotherapy in Subjects with Metastatic Pancreatic Ductal
Adenocarcinoma.
II
D8530C00002 (SERENA-2) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestra nt in Women with Advanced ER-Positive HER2-Negative Breast Cancer. II
D9108C00001 (COAST) A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with
Novel Agents in Subjects wit h Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST).
II
D910CC00001 (COLUMBIA-1) A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1). II
D933IC00003 (BAYOU) Ensayo clínico fase II, aleatorizado, multicéntrico, doble ciego, internacional, comparativo para determinar la eficacia y la seguridad de durvalumab e n combinación con olaparib para el tratamiento en primera línea, en pacientes con cáncer urotelial irresecable en estadio IV inelegibles para tratamiento con cisplatino. II
DIV-SCLC-301 "A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer" II
DS8201-A-J20 3 A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer. II
DS8201-A-U2 01 A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metasta tic Breast Cancer Subjects Who are Resistant or Refractory to T-DM1. II
DS8201-A-U2 04 A PHASE 2, MULTICENTER, OPEN-LABEL, 2-COHORT STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A),
AN ANTI-HER2 ANTIBODY DRUG CONJUGAT E (ADC),FOR HER2-OVER-EXPRESSING OR -MUTATED,
UNRESECTABLE AND/OR METASTATIC NON-SMALLCELL LUNG CANCER (NSCLC).
II
DS8201-A-U2 05 A Phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS-8201a) in HER2-positive, unresectable or metastatic gastric or gastro-esophage al junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen. II
DZB-CS-201 ( FIDES-2) An open label multi-cohort Phase 1/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-2). II
DZB-CS-301 A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene
fusions or FGFR2 gene muta tions or amplifications.
II
E7080-A001-1 11 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid
Tumors.
II
EF-30 (HEPAN OVA) HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) II
ENZART Enzalutamida y radioterapia hipofraccionada en cáncer de próstata localizado de riesgo intermedio. ENZART II
EORTC 1607 “Open label first line, randomized phase II study of CisGem combined or not with pembrolizumab in patients with advanced or metastatic biliary trac t cancer” II
EORTC STUDY 62113-55115 A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarc oma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment II
EORTC-1209- ENTF A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either
differentiated or medullary thyroid cancer progressing after first line therapy.
II
EORTC-1525- LCG Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemoth erapy - (Nivothym). II
EORTC40091 (BOS-2) Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatm ent in patients with resectable liver metastases from wild type KRAS colorectal cancer. II
ESR15-11561- 61 (DUNE) "A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroen teropancreatic or lung origin (the DUNE trial)" II
ETOP 6-14 NI COLAS A feasibility trial evaluating anti-PD1 nivolumab consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/ B NSCLC II
ETOP12-17 (A LERT-lung ) A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC. II
FiHM006 Ensayo fase II para evaluar la evolución de la carga de mutación de KRAS por biopsia
líquida en pacientes con adenocarcinoma ductal pancreático resecable tratados con
tratamiento neoadyuvante NALIRINOX.
II
GC-LTFU-001 “Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells”. II
GECP 17/02 ( REPLAY) A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advan ced non - small cell lung cancer. II
GECP 18/02 ( NADIM II) A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemotherapy alone for the treatment of locally advanced and potential ly resectable nonsmall cell lung cancer (NSCLC) patients” NADIM II. II
GECP16-03 (N ADIM) Ensayo clínico fase II, exploratorio y multicéntrico, de quimioinmunoterapia neo-adyuvante para el tratamiento del cáncer de pulmón no microcítico estadío III operable II
GECP17/04 (T HOMAS) An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations. II
GECP17/05 ( ML40238) Phase II non-randomized study of atezolizumab (mpdl3280a) in combination with carboplatin plus pemetrexed in patients who are chemotherapy-naï ve and have stage IV non-squamous non-small cell lung cancer with asymptomatic brain metastasis. II
GEICAM 2015 -06 (COMETA) A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (C OMETA-Breast Study). II
GEIS 15 ENSAYO CLÍNICO FASE II DE TRATAMIENTO NEOADYUVANTE CON IFOSFAMIDA A DOSIS ALTAS Y RADIOTERAPIA CONCOMITANTE EN SARCOMAS DE P ARTES BLANDAS E IDENTIFICACIÓN DE MARCADORES PREDICTORES DE RESPUESTA II
GEIS 36 (COS YMO) A phase 2, single arm, multi center trial evaluating the efficacy of the COmbination of Sirolimus and cYclophosphamide in metastatic or unresectable Myxoid liposarcoma and chOndrosarcoma. II
GEIS 39 (ABR ADES) “Ensayo fase II de nab-paclitaxel para el tratamiento de tumores desmoides y tumores desmoplásicos de células pequeñas y redondas y sarcoma de E wing en recaída múltiple o refractarios”. II
GEIS 40 Phase II, multicenter, open label, prospective trial for the use of regorafenib as first line treatment for patients with KIT/PDGFR Wild Type GIST II
GEIS 41 A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tum ors (GISTs) . II
GEIS-52 Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas. II
GELLC-7 Estudio multicéntrico, no aleatorizado y abierto, para evaluar la eficacia y seguridad de ibrutinib seguido por consolidación de ibrutinib en combinaci ón con ofatumumab, en pacientes con Leucemia Linfocítica Crónica (LLC) o Linfoma Linfocítico de Células Pequeñas (LLCP) sin tratamiento previo. II
GELTAMO-IM CL-2015 Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Man tle Cell Lymphoma. II
GEM-1802 ( ​E BRAIN-MEL) Phase II, multicenter clinical trial to evaluate the activity of encorafenib and binimetinib administered before local treatment in patients with BRAF m utant melanoma metastatic to the brain. II
GEMCAD 160 1(PIER) "Tratamiento preoperatorio de inducción con 12 semanas de Panitumumab combinado con FOLFOX 6m en una población enriquecida (Quádruple Wil d-Type) de pacientes con cáncer de recto de tercio medio mrT3 y fascia mesorrectal no invadida" II
GEMCAD 170 1 Estudio aleatorizado de fase II para evaluar la eficacia de FOLFIRI + panitumumab en el tratamiento en segunda línea de pacientes con cáncer colorrec tal metastásico RAS no mutado que han recibido FOLFOX + panitumumab en primera línea de tratamiento. II
GEMCAD 170 3 (DUREC) Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial). II
GETHI021 A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in dulthood (GETHI021). II
GETNE-1509 ( TALENT) Estudio de fase II prospectivo, internacional, multicéntrico, abierto, estratificado y exploratorio para evaluar la eficacia y la seguridad de lenvatinib. II
GETNE-2016- 01(RESUNET) "Estudio Fase II para evaluar la eficacia dek retratamiento con sunitinib en pacientes con tumores neuroendocrinos pancreáticos bien diferenciados G 1/2 (pNET) avanzados o metastásicos que ya han fracasado a un tratamiento con sunitinib previo (Estudio RESUNET)". II
GETNE-T1812 (DUTHY) A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinom a-The DUTHY trial. II
GETNE-T1913 (NICE -NEC) A phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally adva nced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin. II
GL0817-01 "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity" II
GO29365 A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATI ON WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA II
GO40290 A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUM AB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. II
GTI-4419-202 An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer. II
HM-EMSI-202 Estudio de Fase 2, de un solo grupo y abierto, de evaluación de la eficacia, la seguridad y la farmacocinética de HM61713 en pacientes con cáncer de pulmón no microcítico (CPNM) con la mutación T790M tras el tratamiento con un inhibidor de a tirosina cinasa del receptor del factor de crecimiento epidérmico (EGFR-TKI) II
I3Y-MC-JPBZ ( MonarcHER) monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of
Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer.
II
I3Y-MC-JPCG A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with
Previously Treated Hormone Recept or-Positive, HER2-Negative, Metastatic Breast Cancer.
II
I3Y-MC-JPCM A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without
Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer.
II
I3Y-MC-JPCP Protocol Addendum I3Y-MC-JPCP(2) An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability when Receiving Abemaciclib for Patients with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer. II
I4D-MC-JTJN A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer. II
I5B-MC-JGDL- II A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Tr eatment of Advanced Soft Tissue Sarcoma II
I5B-MC-JGDP- II A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in th e Treatment of First-Line Metastatic Pancreatic Cancer. II
IBDCL-GELTA MO-2015 Ensayo clínico fase II multicéntrico para Evaluar la eficacia y la seguridad de ibrutinib en combinación con rituximab, gemcitabina, oxaliplatino y dexa metasona seguido de ibrutinib como tratamiento de mantenimiento en pacientes con linfoma difuso de células B grandes de tipo no GCB resistente al tratamiento o recidivante no candidatos a recibir un TACM II
INCB 50465-2 03 (CITADEL-203) Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) II
INCB 50465-2 04 A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204). II
INCB 50465-2 05 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Tre ated With or Without a BTK Inhibitor (CITADEL-205) II
INCB01158-2 06-II A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Parti cipants With Relapsed or Refractory Multiple Myeloma II
INCMGA0012 -201 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma. II
INCMGA0012 -202 A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chem otherapy. II
IRX-2 2015A "A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX 2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squa mous Cell Carcinoma of the Oral Cavity" II
ISA101b-HN- 01-17 A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatmen t of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC). II
J1S-MC-JV01 A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with
Relapsed, Recurrent, or Refractory De smoplastic Small Round Cell Tumor.
II
J1S-MC-JV02 A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Sy novial Sarcoma. II
JCAR017-BC M-001 Ensayo de fase II, multicéntrico, de cohortes múltiples y de un solo brazo para evaluar la eficacia y seguridad de JCAR017 en sujetos adultos con linfo ma no Hodgkin de células B agresivo II
KO-TIP-002 An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma II
KO-TIP-007 The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squa mous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). II
M14-064 Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab. II
M14-239 (LU MINOSITY) Estudio de fase II abierto para evaluar la seguridad y la eficacia de telisotuzumab vedotina (ABBV-399) en pacientes con cáncer de pulmón no microcít ico c-Met+ tratado previamente. II
M16-085 Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Su bjects with Relapsed or Refractory Multiple Myeloma II
MANTA A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Rec eptor Positive Advanced or Metastatic Breast Cancer. II
MCLA-128-CL 02 Phase II study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA- 28/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low-HER2 expression MBC. II
MDV3800-06 A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Can cer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) II
ME-401-003 “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failur e of Two or More Prior Systemic Therapies” II
MedOPP067 ( PARSIFAL 1) A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in p atients with HER2 negative, ER+ metastatic breast cancer. (PARSIFAL 1). II
MedOPP068 ( PALMIRA) International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combinat ion with second-line endocrine therapy in hormone receptor-positive/HER2-negative Advanced Breast Cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment. (PALMIRA). II
MEDOPP089 BioPER A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challen ge upon progression to a palbociclib combination in ER-positive metastatic breast cancer patients (BioPER). II
MedOPP096 - MO39229 (PHERGain) Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study II
MedOPP098 ( EXCAAPE) "Ensayo Clínico de Fase II de la actividad de radio 223 en pacientes con cáncer de próstata metastásico resistente a la castración (CPRCm) con progres ión asintomática durante el tratamiento con acetato de abiraterona o enzalutamida en función del estado mutacional del gen AR-V7" II
MedOPP168 ( OPHELIA) Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer p atients .– The OPHELIA Study – II
MEDOPP199 ( DXCARTES ) NEOADJUVANT LETROZOLE AND PALBOCICLIB IN PATIENTS WITH STAGE II-IIIB BREAST CANCER, HR[+]/HER2[-] PHENOTYPE AND PRE-TREATMENT RE CURRENCE SCORE® (RS) RESULT 18-25 OR 26-100 BY THE ONCOTYPE DX BREAST RS ASSAY. ANALYSIS OF RS AND PATHOLOGICAL CHANGES AT SURGERY (DxCARTES TRIAL) . II
METTEN-01 ( CAIBER) Ensayo fase II, aleatorizado, abierto, multicéntrico, de tratamiento neoadyuvante con quimioterapia y trastuzumab con o sin la adición de metformin a en mujeres diagnosticadas de cáncer de mama primario HER2/ErbB2 positivo. II
MIN-003-180 6 (CLINGLIO) A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2 -hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment. II
MO29112 (M ODUL) ENSAYO CLÍNICO MULTICÉNTRICO RANDOMIZADO, DE TRATAMIENTO DE MANTENIMIENTO BASADO EN
BIOMARCADORES PARA PRIMERA LÍNEA DE CÁNCER COLORRECTAL METASTÁSICO (MODUL)
II
MO39107 A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN
COMBINATION WITH OBINUTUZUMAB OR RITUXIMA B ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA, MARGINAL ZONE LYMPHOMA AND WALDENSTRÖM MACROGLOBULINEMIA
II
MOM-M254- 001 A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura II
MOR208C203 A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients Wit h Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) II
MRG106-11-2 01 SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomars en (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype. II
MS100070-01 60 Phase II multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine /carboplatin alone in patients with unresectable or metastatic urothelial carcinoma (UC) who have not received prior systemic therapy and who are ineligible to receive cisplatin-based therapy. II
MS200095-00 22 Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exó n 14 de MET (METex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino. II
MS200095-00 31(INSIGHT-31) A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer ( NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd
generation EGFR-tyrosine kinase inhibitor therapy.
II
MS200647-00 37 A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 E xpressing Advanced Non-small Cell Lung Cancer. II
MS200647-00 47 A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metasta tic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy. II
MS200647-00 55 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer. II
MS201944-01 70 A Phase IIa, single-arm, multicenter study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squamous non-small-cell lung cancer. II
MT-3724_NH L_001 Safety, Pharmacodynamics and Efficacy of MT- 3724 for the Treatment of Patients with Relapsed or Refractory DLBCL II
MYL-14020-3 001 "Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-l ine Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer" II
ODO-TE-B201 (CONTESSA 2) A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Pos itive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane. II
ODO-TE-B202 (CONTESSA 3) A multicenter, phase II, study of Tesetaxel plus three diferent PD_L-1 inhibitors in patients with triple negative , locally advanced or metastasic breas t cancer and tesetaxel monotherapy in elderly patients with HER2 negative , LAMBC. II
ONCOS C719 (MESOS) A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus , and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma. II
ONT-380-206 Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with P retreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma II
OZM-060 (eV OLVE) A proof of concept, multi-centre, clinical trial of the combination cediranib-olaparib at the time of disease progression on
PARP inhibitor in ovarian ca ncer.
II
PETHEMA-BLI N-01 Estudio de fase II, abierto, para evaluar el efecto de Blinatumonab administrado durante la consolidación para reducir el nivel de enfermedad residua l (Er) evaluada mediante citofluorometría en pacientes adultos hasta 55 años con leucemia linfoblástica aguda (LLA) de alto riesgo (AR) sin Cromosoma Filadelfia (Ph-) con buena respuesta (ER<0.1%) después del tratamiento de inducción. II
PonaZero Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 mg o n Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, who had previously Achieved a Deep Molecular Response with Imatinib. II
QRT-SOGUG Estudio Clínico en Fase II aleatorizado de radioterapia, hormonoterapia y quimioterapia con docetaxel versus radioterapia y hormonoterapia, en paci entes afectados de cáncer de próstata localizado de alto riesgo (Estadio III Y IV). II
R1979-ONC-1 625 “AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATI ENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA” II
R2810-ONC-1 540 (REGENERON) A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CU TANEOUS SQUAMOUS CELL CARCINOMA. II
RG-13-277 An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. II
RVT-1401-20 03 A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia. II
SGN22E-001 ( EV-201) A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally
advanced or metastatic urotheli al cancer who previously received immune checkpoint inhibitor (CPI) therapy.
II
SGNLVA-002 Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of
Patients with Unresectable L ocally-Advanced or Metastatic Triple-Negative Breast Cancer.
II
SGNTV-002 Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen. II
SMS-0472B ( NEOFOX) A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer. II
SOGUG-2016- A- IEC(REN)-10(INMUNOSUN) "Estudio fase II para evaluar la eficacia y seguridad del tratamiento con sunitinib en pacientes con carcinoma renal de células claras metastásico que han progresado al tratamiento con inmunoterapia en primera línea" II
SOLTI 1303 (P ATRICIA) PATRICIA: Ensayo clínico fase II de la combinación de palbociclib y trastuzumab con o sin letrozol en pacientes postmenopáusicas con cáncer de mam a localmente avanzado o metastásico HER2-positivo previamente tratado II
SRA-MMB-30 1 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy II
SUNNIFOREC AST A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated a nd Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma. II
SYD985.002 ( TULIP) “A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice i n patients with HER2-positive unresectable locally advanced or metastatic breast cancer” II
TACTI-002 (P0 15) TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metast atic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist). II
TAS-120-201 A Phase 2 Study of TAS-120 in Metastatic Breast Cancer Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications. II
TDM4529g/B O25430 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH O THER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD-SPONSORED TRASTUZUMAB EMTANSINE STUDY II
TPU-TAS-120- 101-II A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECE PTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR MULTIPLE MYELOMAWITH FGF/FGFR-RELATED ABNORMALITIES. II
TPX-0005-01( TRIDENT-1) A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Pa tients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). II
TRASTS-II (GE IS 37) Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos II
TTD-14-05 (SE QUENCE) Estudio fase I-II con Nab-paclitaxel (Abraxane®) y gemcitabina seguido de FOLFOX
modificado (AG-mFOLFOX) en pacientes con cáncer de páncreas me tastásico no tratado.
II
TTD-16-03 (A FEMA) Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment wi th FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. II
UC-0140/160 6 UCBG-105-BIG 16-01 (ULTIMATE) A phase II trial testing durvalumab combined with endocrine therapy in patients with ER+/her2- breast cancer eligible for neoadjuvant endocrine ther apy and who present CD8+ T cell infiltration after 4-6 weeks exposure to immune-attractant. II
UTX-TGR-205 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and T GR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma II
VHIO16001 - EORTC 1604 (MOTRICOLOR) A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced che motherapy resistant colorectal cancer and MSI-like molecular signature . II
VHIO17001 (T OPIC) Phase II trial of pembrolizumab in combination with doxorubicin in Advanced,Recurrent or Metastatic endometrial cancer. II
VHIO19001( MONEO) Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with respectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) – MONEO Study. II
W00090 GE 2 01 (ANCHOR) Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAFV600E -mut ant Metastatic Colorectal Cancer. II
WO30085 (K ATE 2) A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBOCONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSIN E IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY II
SOLTI-1502 ( ARIANNA) TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAS T CANCER. II
QUIWI A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus plac ebo in adult patients with newly diagnosed FLT3 wild-type AML II
ZWI-ZW25-20 2 Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant. II
207497-II (DR EAMM6) A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GS K2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – (DREAMM 6) II
AFM13-202 ( REDIRECT) A phase II Open label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with relapsed or refractory CD30-positive Peripheral T- cell Lymphoma or Transformed Mycosis Fungoides (REIDRECT) II
ACT16105 An open-label randomized Phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s
choice in premenopausal and postmenopaus al patients with estrogen receptor-positive, HER2-negative locally
advanced or metastatic breast cancer with prior exposure to hormonal therapies.
II
MK-7339-009 An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical B enefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009). II
20180115 (M ASTERKEY-115) Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With nresectable/Metastatic Stage IIIB-IVM1c Melano ma Who Have Progressed on Prior Anti-PD-1 Based Therapy. II
EORTC-1762- STBSG( REDUCE) Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE", II
SOLTI-1716 (T ATEN) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor treatment. II
SOLTI-1804 ( HER2PREDICT) HER2-PREDICT: TRANSLATIONAL STUDY OF TUMOR SAMPLES FROM DS8201-A-U301 AND DS8201-A-U302 TRIALS. II
CSEG101A220 3 A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on r enal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST). II
16-214-05 A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Pat ients with Locally Advanced or Metastatic Solid Tumors. II
53718678RSV 2005 (FREESIA) A randomized, double blind, placebo-controlled study to evaluate the clinical outcomes, antiviral activity, safety, tolerability, pharmacocinetics, and pharmacocinetics/pharmacodynamics of JNJ-53718678 in adult and adolescent hematopoietic stem cell transplant recipients with respiratory syncytial virus infection of the upper respiratory tract. II
MK-1454-002 A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Co mbination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy. II
EORTC-1745- ETF-BCG(APPALACHES) A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk
ER+/HER2- early breast cancer (APPALA CHES).
II
209229 (INDU CE 3) A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma . II
MS200647-00 17 A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy. II
MedOPP190 ( LUZERN) Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-p ositive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancers with either Germline BRCA-mutated or Germinal BRCA-wild-type and Homologous Recombination Deficiency (HRD). II
4SC-202-3-20 18 (MERKLIN 2) A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresecta ble/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study. II
BOT112-02 Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis fro m colorectal cancer or gastric/gastrooesophageal junction cancer. II
MK-7902-009 A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pe mbrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009). II
GO41836 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAPY IN PATIENTS WHO ARE ctDNA POSITIVE AFTER SURGICAL RESECTION OF STAGE II-III NON-SMALL CELL LUNG CANCER. II
D6018C00004 (DUETTE) A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum- Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatment, II
GECP 19/01 ( CUBIK) CLINICAL UTILITY OF LIQUID BIOPSY AS A TOOL TO ASSESS THE EVOLUTION OF BRIGATINIB TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EML4-ALK TRANSLOCATION: AN EXPLORATORY STUDY II
M16-109 A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis II
GO40558 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUM AB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA. II
CINC280I1220 1 A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembroliz umab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1≥ 50%. II
D4194C00009 (DUART) A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Smal l Cell Lung Cancer Who Are Ineligible for Chemotherapy (DUART). II
CINC280J122 01 A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as first line treatment for locally advanced or metastatic non-small cell lung cancer patients with MET exon 14 skipping mutations. II
MK-3475-03A A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A. II
MK-3475-03B Estudio de fase 1b/2 de terapias inmunitarias y dirigidas combinadas en participantes con carcinoma renal (CR) (U03): subestudio 03B. II
CCTL019C220 2 (BIANCA) Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refract ory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA). II
IFOM-CPT005 /2019/PO004 (PEGASUS) POST-SURGICAL LIQUID BIOPSY - GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS. II
ZWI-ZW25-20 3 A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers. II
SOLTI-1718 ( NEREA) Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA t rial). II
MEDOPP234 ( ZZ-FIRST) Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormo ne-naïve Prostate Cancer. II
CA030-001 A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors. II
SGNTUC-017 (MOUNTAINEER) MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer. II
ETOP 15-19 A BC-lung A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-muta nt non-small cell lung carcinoma with acquired resistance. II
GETNE-T1914 (CABATEN) Exploratory basket trial of cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system – The CABATEN study. II
CITRIC Multicenter, open-label, randomized, 2-arm, phase
II study to evaluate the efficacy and safety of
cetuximab plus irinotecan rechallenge
compared wit h investigator's choice of
therapy in the third-line setting in ctDNA
genomically selected patients with metastatic
colorectal cancer (CITRIC Study).
II
MedOPP240 ( METALLICA) STUDY TO EVALUATE THE EFFECT OF METFORMIN IN THE PREVENTION OF HYPERGLYCEMIA IN HR[+]/HER2[-] PIK3CA-MUTATED ADVANCED BREAST CANCER PATIENTS TREATED WITH ALPELISIB PLUS ENDOCRINE THERAPY. THE METALLICA.
STUDY
II
GEICO 78-C ( ATOMICC) A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer afte r chemo-radiation. II
A PHASE 1B/2 A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND T OLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA II
MK-3475-495 A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475,SCH 900475) Based Combination Therapy for Advanced Non-S mall Cell Lung Cancer (KEYNOTE-495; KeyImPaCT). II
MK-3475-799 Ensayo de fase 2 de pembrolizumab (MK-3475) en combinación con quimioterapia con doblete de platino y radioterapia para participantes con cánce r de pulmón no microcítico (CPNM) en estadio III irresecable y localmente avanzado (KEYNOTE-799). II
BRIGATINIB-2 002 Brigatinib en pacientes con cáncer de pulmón de células no pequeñas avanzado con linfoma anaplásico cinásico positivo (ALK+) cuyo cáncer ha progre sado durante el tratamiento con alectinib o ceritinib. II
MK-3475-782 A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Tr eatment for Non-Small Cell Lung Cancer (KEYNOTE-782). II
CL02-ORY-10 01AML (ALICE) A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in firs t line therapy. II
B9991023-II A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHE MOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES. II
MK-3475-629 629-00 A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cu taneous SquamousCell Carcinoma (R/M cSCC). II
MK-3475-100 A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Rec urrent Ovarian Cancer (KEYNOTE -100) II
MK-3475-427 "Ensayo clínico de fase II, abierto y de un solo grupo para evaluar el uso de pembrolizumab (MK-3475) en monoterapia en el carcinoma renal metastá sico (CRm) o localmente avanzado (KEYNOTE-427)" II
MK-3475-365 Ensayo de fase Ib/II de tratamientos combinados con pembrolizumab (MK-3475) en el cáncer de próstata resistente a la castración metastásico (CPRC m) (KEYNOTE-365) II
M14POS (POS EIDON-II) Phase I/prospective randomised phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-00 32 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment II
MK-3475-052 Ensayo clínico de fase II de pembrolizumab (MK-3475) en sujetos con cáncer urotelial avanzado/irresecable o metastásico II
MK-3475-164 A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Sta ge IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164) II
EORTC-22114 -4011 (TOPGEAR) A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer II
MK-3475-010 A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Squamous Histology Non- Small Cell Lung Cancer. II
AMCMEDON C17-010 (NAPAN) A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5
fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy.
II
04-30 (Oncon ova) A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndr ome After Failure of a Hypomethylating Agent III
1333-GUCG ( PEACE III) A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptoma tic castration resistant prostate cancer patients metastatic to bone. III
15-007 A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno- Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell transplant III
17712 - ( 310 4007) ESTUDIO EN FASE III MULTINACIONAL, ALEATORIZADO, CON DOBLE ENMASCARAMIENTO Y CONTROLADO CON PLACEBO SOBRE LA EFICACIA Y SEGU RIDAD DE ODM-201 EN VARONES CON CÁNCER DE PRÓSTATA NO METASTÁSICO DE ALTO RIESGO RESISTENTE A LA CASTRACIÓN III
2125-MEL-30 1 A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma. III
2215-CL-0301 A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myel oid Leukemia (AML) With FLT3 Mutation III
2215-CL-0304 (MORPHO) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Adminitered as Mantinance Therapy Fol lowing Allogenic Transplant for Patients with FLT3/ITD AML III
54767414AM Y3001 (ANDROMEDA) A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamet hasone (CyBorD) Compared With CyBorD Alone in Newly diagnosed Systemic AL Amyloidosis III
54767414M MY3007 A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combin ation with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy III
54767414M MY3014 A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexa methasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy. III
54767414SM M3001 A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple M yeloma III
56021927PCR 3001(ACIS) Estudio de fase III, aleatorizado, controlado con placebo y doble ciego de JNJ-56021927 en combinación con acetato de abiraterona y prednisona en c omparación con acetato de abiraterona y prednisona en sujetos con cáncer de próstata metastásico resistente a la castración (CPRCm) que no han recibido nunca quimioterapia III
56021927PCR 3003 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Ca ncer Receiving Treatment with Primary Radiation Therapy. III
56021927PCR 3011 (PROTEUS) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Ca ncer Who are Candidates for Radical Prostatectomy. III
62092-22092 (STRASS) STRASS - A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcoma (RPS )STRASS III
63935937MD S3001 (Imeteslstat) A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome ( MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment III
7465-CL-0301 (EV-301) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced o r Metastatic Urothelial Cancer (EV-301). III
8951-CL-0301 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with
Placebo Plus mFOLFOX6 as Fir st-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally
Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
III
9785-CL-0335 (ARCHES) ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivati on Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC). III
A5481008 (TR IO-022) A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER(+), HER2(-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE. III
ABI-007-PAN C-003 A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF nab®-PACLITAXEL PLUS
GEMCITABINE VERSUS GEMCITABINE ALONE AS ADJUVANT THERAPY IN SUBJECTS WITH SURGICALLY RESECTED PANCREATIC ADENOCARCINOMA.
III
ACE-536-LTFU -001 A PHASE 3B, OPEN-LABEL, SINGLE-ARM, ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN
SUBJECTS WHO HAVE PARTICIPATED IN OTHER LUSP ATERCEPT (ACE-536) CLINICAL TRIALS.
III
ACE-536-MDS -001 (Luspatercep) A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemi a Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions III
ACE-536-MDS -002 A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Ane mia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions. III
ACE-CL-311/D 8221C00001 “Ensayo fase 3, aleatorizado, multicéntrico y abierto para comparar la eficacia y seguridad de acalabrutinib (ACP-196) en combinación con venetoclax con y sin obinutuzumab, con la eficacia y seguridad de la quimioinmunoterapia elegida por el investigador en pacientes con leucemia linfocítica crónica sin mutación del(17p) o TP53 no tratada previamente” III
ACE-LY-308 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma III
ADXS001-02 PHASE 3 STUDY OF ADXS11-001 ADMINISTERED FOLLOWING CHEMORADIATION AS ADJUVANT TREATMENT FOR HIGH RISK LOCALLY ADVANCED CER VICAL CANCER: AIM2CERV. III
AFT05 - ABCS G 42 - BIG 14-03 (PALLAS) "Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyu vante estándar en cáncer de mama primario con receptores hormonales positivos (RH+) y HER2-negativo". III
AFT-38 (PATI NA) "Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2 + tratamiento endocrino frent e a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de mama metastásico positivo para receptores hormonales (HR+)/positivo para HER2 " III
AG120-C-005 "A Phase 3, Multicenter, Randomized, Double-Blind Study of AG-120 vs. Placebo in Previouslytreated Subjects with Nonresectable or Metastatic Chol angiocarcinoma with an IDH1 Mutation" III
AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation III
AG348-C-006 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF AG-348 IN NOT REGULARLY TR ANSFUSED ADULT SUBJECTS WITH PYRUVATE KINASE DEFICIENCY
III
AG348-C-011 An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies III
AG881-C-004 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of AG-881 in Subjects with  Residual/Recurrent Grade 2 Glioma with an I DH1 or IDH2 Mutation. III
AML003/(UY A26495) Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxan trone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years).
with Relapsed/Refractory Acute Myeloid Leukemia (AML)
III
AP26113-13- 301 A Phase 3 Multicenter Open-label Study of Brigatinib(AP26113) versus Crizotinib in Patients with ALK-positive
Advanced Lung Cancer.
III
ARGX-113-18 01 “A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg /kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia” III
ARN509-003 SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Re sistant Prostate Cancer III
ARO 012 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects
with Advanced or Metastatic Gastrointestinal Stromal T umors with a D842V Mutation in the PDGFRA
Gene
III
ARRAY-818-3 02 A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs.
Irinotecan/Cetuximab or Infu sional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
III
ASP-1929-301 A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s
Choice Standard of Care for t he Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be
Systemic Therapy.
III
ASPER-III-19- 1 A Phase 3, Double-Blind, Multicentric, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability ofltraconazole Dry Powde r for Inhalation for the Prevention of Invasive Mould Disease in Patients with Acute Leukaemia and Neutropaenia. III
A-US-52030-3 28 (SPINET) "A Phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of lanreotide Autogel/Depot 120 mg plus BSC vs. pla cebo plus BSC for tumor control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung neuroendocrine tumors" III
AV001 A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic M yelogenous Leukemia III
B0661037 A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATI ON FOR THE TREATMENT OF A VENOUS HROMBOEMBOLIC EVENT III
B1931030 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTO RY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE. III
B7461006 “A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LIN E TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER” III
BAY1841788 /17777 (ARASENS) A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer. III
BAY80-6946/ 17833 A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunoch emotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 III
BAY88-8223/ 15396 (ERA 223) Estudio de fase III, aleatorizado, doble ciego y controlado con placebo, de dicloruro de radio 223 en combinación con acetato de abiraterona y predni sona/prednisolona en el tratamiento de pacientes con cáncer de próstata resistente a la castración (CPRC) con metástasis predominantemente óseas en pacientes asintomáticos o con síntomas leves, que nunca han recibido quimioterapia III
BB608-303CR C (CanStem303C ) A Phase III Study of BBI-608 in combination with 5- Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC). III
BGB-290-303 A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with noperable Locally Advanced or Meta static Gastric Cancer that Responded to Platinum-based First-line Chemotherapy. III
BGB-3111-30 2 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton?s Tyrosine
Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström?s Macroglobulinemia (WM)
III
BGB-3111-30 5 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leuke mia or Small Lymphocytic Lymphoma. III
BGB-3111-30 6 “A Phase 3 Randomized, Open-Label, Multicenter Study comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in P atients with Previously Untreated Mantle Cell Lymphoma who are ineligible for Stem Cell
Transplantation”
III
BGB-A317-30 1 A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Pa tients with Unresectable Hepatocellular Carcinoma. III
BGB-A317-30 2 A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Se cond Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma. III
BGB-A317-30 6 A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with C hemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. III
BGOG-EN5/E NGOT-EN5/SIENDO An Investigator-Sponsored Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Ad vanced or Recurrent Endometrial Cancer. III
BLU-285-1303 An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST). III
BO25126/BIG 4-11(APHINITY) ESTUDIO MULTICÉNTRICO, DOBLE CIEGO, RANDOMIZADO, CONTROLADO CON PLACEBO, PARA COMPARAR QUIMIOTERAPIA MÁS TRASTUZUMAB Y P LACEBO CON QUIMIOTERAPIA MÁS TRASTUZUMAB Y PERTUZUMAB, COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CÁNCER DE MAMA PRIMARIO HER2-POSITIVO OPERABLE. ESTUDIO APHINITY PERTUZUMAB ADYUVANTE Y HERCEPTIN EN TRATAMIENTO INICIAL DE CÁNCER DE MAMA. III
BO25323 A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF O BINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT-199) VERSUS OBINUTUZUMAB AND CHLORAMBUCIL IN PREVIOUSLY UNTREATED PATIENTS WITH CLL AND COEXISTING MEDICAL CONDITIONS. III
BO28407 (KAI TLIN) A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHR ACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER III
BO40336 (ALI NA) A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BA SED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ³ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA INASE-POSITIVE
NON-SMALL CELL LUNG CANCER.
III
BO40747 (IM PASSION050) A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR P LACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN+ CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL+ TRASTUZUMAB+ PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER. III
BP40657 A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTA NEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN ATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER III
Brigatinib-30 01 A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positiv e Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib XALKORI®). III
C0371004 AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY A ND SELECTED SAFETY DATA OF FACTOR IX (FIX) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C£2%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES (NAB) TO ADENO-ASSOCIATED VIRUS VECTOR (AAV)-SPARK100” III
C3441021 (TA LAPRO 2) A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESI STANT PROSTATE CANCER. III
C935788-057 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoim mune Hemolytic Anemia III
CA045001/18 -214-08 A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unres ectable or Metastatic Melanoma. III
CA209-026 Ensayo fase 3, abierto y aleatorizado, de nivolumab frente a la quimioterapia de elección del investigador como tratamiento de primera línea del cán cer de pulmón no microcítico (CPNM) PD-L1+ en estadio IV o recidivante III
CA209-057 Ensayo fase 3, aleatorizado, abierto, de BMS-936558 (nivolumab) frente a docetaxel en el cáncer de pulmón no microcítico (CPNM) metastásico no ep idermoide tratado previamente III
CA209-067 Estudio fase 3, aleatorizado, doble ciego, de nivolumab en monoterapia o nivolumab combinado con ipilimumab frente a ipilimumab en monoterapia en sujetos con melanoma irresecable o metastásico no tratado previamente. III
CA209-214 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untre ated, Advanced or Metastatic Renal Cell Carcinoma III
CA209-227 Ensayo fase III, abierto, aleatorizado, de nivolumab o nivolumab más ipilimumab, frente a quimioterapia basada en doblete de platino en sujetos con cáncer de pulmón no microcítico (CPNM) en estadio IV o recidivante, que no han recibido quimioterapia previamente. III
CA209-274 "Estudio de fase 3 aleatorizado, doble ciego, multicéntrico, de nivolumab como tratamiento adyuvante frente a placebo en sujetos con Carcinoma ur otelial invasivo de alto riesgo". III
CA209-331 Estudio Fase 3 abierto, aleatorizado, de nivolumab o quimioterapia en sujetos con cáncer microcítico de pulmón en recaída después de quimioterapia de primera línea basada en platino III
CA209-451 A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Ther apy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. III
CA209-577 A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer. III
CA209-649 A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previ ously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. III
CA209-651 An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cis platin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). III
CA209-722 “Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed III
CA209-7FL A Randomized, multicenter, double-lbind, placebo -controlled phase 3 study of nivolumab VS placebo in combination with neoadjuvant chemothera py and adjuvant endocrine Therapy in the treatment of high-risk, stage II-III estrogen receptro-positive (ER+), human epidermal growth factor receptro 2- negative (HER2-) breast cancer. III
CA209-816 Randomized, Open-Label Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC III
CA209-817 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced malignancies III
CA209-8HW A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in P articipants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. III
CA209-8Y8 A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors. III
CA209-915 A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherap y after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma III
CA209-9ER A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib ver sus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. III
CA2099LA A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stag e IV Non-Small Cell Lung Cancer (NSCLC). III
CACZ885U23 01 (CANOPY-1) A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab
plus platinum-based doublet ch emotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1).
III
CAMN107AIC 05 A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-posi tive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID III
CanStem111P Estudio en fase III de la combinación de BBI-608, nab-paclitaxel y gemcitabina en pacientes adultos con adenocarcinoma pancreático metastásico. III
CDRB436F230 1 - BRF115532 COMBI-AD: Estudio de fase III, aleatorizado y doble ciego de dabrafenib (GSK2118436) en COMBInación con trametinib (GSK1120212) frente a dos pla cebos en el tratamiento ADyuvante del melanoma de alto riesgo con la mutación BRAF V600 tras resección quirúrgica. III
CINC424B240 1 (Response) Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients Wit h Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2) III
CL3-95005-00 6 (SOLSTICE) An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab
to capecitabine in combinatio n with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study).
III
CLDK378A230 1 Estudio de fase III, multicéntrico, aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV, que no han sido tratados previamente. III
CLEE011A230 1(MONALEESA 2) A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hor mone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease. III
CLEE011E230 1(MONALEESA 7) A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen
and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women
with hormone receptor positive, HER2-negative, advanced breast cancer
III
CLEE011O123 01C (TRIO033 NATALEE) A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]:NATALEE). III
CMBG453B12 301 A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients wit h intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2). III
CO-338-014(A RIEL-3) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemoth erapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial
Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
III
CO-338-043(A RIEL 4) "A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer" III
CO-338-087 ( ATHENA) ATHENA (A Multicenter, Randomized, Double-Blind, PlaceboControlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivoluma b as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy). III
CO39262 (TRI LOGY) A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PL ACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION−POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR
METASTATIC MELANOMA.
III
CO40016 A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FO R PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR– POSITIVE, HER2-NEGATIVE BREAST CANCER . III
CO41101 A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS
PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER.
III
CO41685 A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF VENETOCLAX AND OBINUTUZUMAB VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (FCR)/
BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION
III
CP-MGAH22- 04-220875(SOPHIA) EA Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the
Treatment of Patients with HER2+ M etastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment.
III
CRAD001T23 02 (RADIANT-4) A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE III STUDY OF EVEROLIMUS (RAD001) PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BE ST SUPPORTIVE CARE IN THE TREATMENT OF PATIENTS WITH ADVANCED NET OF GI OR LUNG ORIGIN III
CR-AIR-009 ( HATCY) A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101 , a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study) III
CSEG101A230 1 “Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de dos dosis de crizanlizumab frente a placebo, con o sin hidroxiurea/hidroxicarbamida, en pacientes adolescentes y adultos con enfermedad de células falciformes con crisis vaso-oclusivas (STAND)” III
CSL654-3003 A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Su bjects with Hemophilia B. III
CSL964-2001 A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prE vention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study) III
D0816C00010 (SOLO 3) Estudio abierto, multicéntrico, controlado y aleatorizado de fase III para evaluar la eficacia y seguridad del olaparib en monoterapia frente a la quimi oterapia con agente único de elección por el médico en el tratamiento del cáncer ovárico
recidivante sensible al platino en pacientes portadoras de las mutaciones germinales BRCA1/2.
III
D0816C00014 (OReO) A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovar ian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO). III
D0816C00018
( LUCY)
“LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study. A Phase IIIb, Single-arm, Open-label Multicentre Study of O laparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations” III
D0816C00020 (OPINION) OPINION - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non- Germli ne BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. III
D0818C00001 (SOLO1) Ensayo fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de mantenimiento con olaparib en monoterapia en pacientes con cá ncer de ovario avanzado, estadio IIIb-IV de la FIGO, con mutación de BRCA que están en respuesta completa o parcial después de quimioterapia de primera línea basada en platino. III
D081CC00006 Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos
paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de
olapari b frente a placebo como tratamiento adyuvante de pacientes con
cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de
BRCA1/2, que han finalizado el tratamiento local y la quimioterapia
neoadyuvante o adyuvante
III
D081FC00001 (POLO) Estudio de Fase III, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, de la monoterapia de antenimiento con olaparib en paciente s con cáncer de páncreas metastásico con mutación de gBRCA cuya enfermedad no ha progresado con una quimioterapia de primera línea basada en el platino. III
D081SC00001 (PROpel) Ensayo en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo de olaparib y abiraterona en comparación con placebo y abirater ona como tratamiento de primera línea en varones con cáncer de próstata metastásico resistente a la castración. III
D3614C00001 (CAPITELLO) DB, Rando study assigned the efficacy and Safety of Capivasertib+pacli VS placebo+pacli as 1L for pa with histologically confirmed , locally advanced ( inoparable)or M1 TNBC. III
D4191C00004 (ARTIC) A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who Have Received at Least Two Prior Systemic reatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) III
D419BC00001 (DANUBE) Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico,
internacional, de MEDI4736 en monoterapia y MEDI4736 en combinación
con tremeli mumab frente a tratamiento de referencia con quimioterapia
como primera línea en pacientes con cáncer de vejiga urotelial irresecable en estadio IV.
III
D419JC00001 (POTOMAC) A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Th erapy Versus BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC). III
D5164C00001 (ADAURA) A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Selected Population with Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer (THYME) III
D933QC0000 1(ADRIATIC) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Co nsolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC). III
D933RC00001 (NIAGARA) A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabi ne+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA). III
D933SC00001 (Nile) Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico, internacional de durvalumab en combinación con el tratamiento estándar con quimio terapia y durvalumab en combinación con tremelimumab y el tratamiento estándar con quimioterapia frente al tratamiento estándar con quimioterapia solo, en primera línea en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico. III
DCC-2618-03- 001 (INVICTUS) A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced c-KIT/PD GFRA Gastrointestinal Stromal TUmorS who have Received Prior Treatment with Imatinib, Sunitinib, and/or Regorafenib. III
DCC-2618-03- 002 (INTRIGUE) A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal T umors after Treatment with Imatinib. III
DIV-SCLC-301 -III A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line
Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
III
DREAMM 7 ( GSK 207503) DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the combination of Belantamab Mafodotin , Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of ratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma. III
DS8201-A-U3 02 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. III
DS8201-A-U3 03 A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A,
AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR
HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS.
III
DU176b-D-U3 12 A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Com pare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE) III
E7080-G000-3 07 (CLEAR) A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembroliz umab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR). III
EF-27 (PANO VA-3) PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for f ront-line treatment of locally-advanced pancreatic adenocarcinoma. III
EFC12522 A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velca de®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant III
EFC15467 ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B. III
EGF106708 (A LTTO) A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HE R2/ErbB2 positive primary breast cancer. III
EGF106903 ( NEO ALTTO) A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with H ER2/ErbB2 positive primary breast cancer . III
Elderly MCL-R 2 Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additi onal Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma III
EMR100070-0 05 Ensayo de fase III, abierto y multicéntrico de avelumab (MSB0010718C) frente al doblete con base de platino como tratamiento de primera línea del c áncer de pulmón no microcítico PD-L1+ recurrente o en estadio IV III
ENGOT OV41 (ANITA) A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months. III
ENGOT-Cx10/ GEICO 68-C/ BEAT cc A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Pacl itaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix. III
EORTC 1203- GITCG (INNOVATION) INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TR IAL III
ETOP 13-18 ( BEAT-meso) Ensayo clínico Fase III multicéntrico aleatorizado que compara atezolizumab más bevacizumab y la quimioterapia habitual con bevacizumab y la quim ioterapia habitual como tratamiento de primera línea para el mesotelioma pleural maligno III
FLUGAZA A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients wi th newly diagnosed acute myeloid leukemia III
GCP#05.01.02 0 (Nicord II) A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Pro genitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies III
GEFCAPI 04 A randomised phase III trial comparing a strategy based on molecular analysis to the empiric strategy in patients with
carcinoma of an unknown prim ary (CUP).
III
GEM2014MAI N Estudio fase III nacional, multicéntrico, abierto, aleatorizado, de tratamiento de mantenimiento con Lenalidomida y dexametasona versus Lenalidomi da, dexametasona y MLN9708 tras trasplante autólogo de progenitores hematopoyéticos para pacientes con mieloma múltiple sintomático de nuevo diagnóstico. III
GEM2017FIT Tratamiento de inducción con bortezomib, melfalán y prednisona (VMP) seguido de lenalidomida y dexametasona (Rd) frente a carfilzomib, lenalido mida y dexametasona (KRd) más/menos daratumumab, 18 ciclos, seguido de tratamiento de consolidación y mantenimiento con lenalidomida y daratumumab: un ensayo clínico de fase III, multicéntrico, aleatorizado para pacientes adultos mayores, de entre 65 y 80 años, con buen estado general y mieloma múltiple de nuevo diagnóstico. III
GEM-CLARID EX Lenalidomida y dexametasona (Ld) versus Claritromicina/Lenalidomida [Revlimid®]/Dexametasona (BiRd) como tratamiento inicial del Mieloma Múlt iple. III
GETNE-1206 ( SEQTOR) Estudio abierto y aleatorizado para comparar la eficacia y la seguridad de everolimus seguido de quimioterapia con STZ-5FU tras la progresión o la sec uencia invertida, quimioterapia con STZ-5FU seguida de everolimus tras la progresión, en tumores neuroendocrinos pancreáticos (TNEP) avanzados y progresivos (estudio SEQTOR) III
GETUG-AFU 2 1 ( PEACE 1) A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOU T ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER. III
GETUG-AFU 2 3 (PEACE-2 ) A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of rela pse. III
GINECO-OV2 36b (ATALANTE) A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or per itoneal cancer treated by platinum-based chemotherapy and bevacizumab. III
GLLC-EARLY Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Disease Progre ssion (GELLC-8). III
GO29436 ESTUDIO FASE III, ABIERTO, ALEATORIZADO, DE MPDL3280A (ANTICUERPO ANTI-PD-L1) EN COMBINACIÓN CON CARBOPLATINO + PACLITAXEL CON O SIN BEVACIZUMAB COMPARADO CON CARBOPLATINO + PACLITAXEL + BEVACIZUMAB EN PACIENTES CON CÁNCER DE PULMÓN NO EPIDERMOIDE NO MICROCÍTICO EN ESTADIO IV QUE NO HAN RECIBIDO QUIMIOTERAPIA PREVIA III
GO29527 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF
ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PD-L1−SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER.
III
GO30081 ESTUDIO FASE III, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE CARBOPLATINO MÁS ETOPÓSIDO CON O SIN ATEZOLIZUMAB (AN TICUERPO ANTI-PD-L1) EN PACIENTES CON CÁNCER DE PULMÓN MICROCÍTICO EN ETAPA AVANZADA NO TRATADO III
GO39942 (PO LARIX) A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA III
GO40241 A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH A TEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED
CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON−SMALL CELL LUNG CANCER.
III
GO41767 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB PLUS
CARBOPLATIN AND ETOPOSIDE WITH OR WITHOU T TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH
UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
III
GRASPANC 2 018-01 A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients wit h Pancreatic Adenocarcinoma. III
I3Y-MC-JPBL MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Wo men with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer. III
I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus
Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
III
I4T-MC-JVCY Estudio multicéntrico, aleatorizado y doble ciego, en el que se evalúa erlotinib en combinación con ramucirumab o placebo en pacientes con cáncer d e pulmón no microcítico metastásico y mutaciones activadoras de EGFR, previamente sin tratar III
IBCSG 24-02( SOFT) Ensayo en fase III para evaluar el papel de la supresión de la función ovárica y el papel de exemestano como tratamientos adyuvantes para mujeres p remenopáusicas con cáncer de mama endocrino sensible. III
IBCSG 35-07 BIG 1-07(SOLE) A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer. III
IBCSG 59-19 / BIG 18-02 (POLAR) A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone f or patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer. III
IMGN853 040 3 (FORWARD1) FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investiga tor’s Choice of Chemotherapy in Women with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer. III
IMMU-132-05 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients wi th Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments. III
IMMU-132-09 Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with
Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast
Cancer (MBC) who have failed at least two prior chemotherapy regimens.
III
INCB 39110-3 01 (GRAVITAS 301) GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Tr eatment of First-Line Acute Graft-Versus-Host Disease III
INCB 54828-3 02 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302). III
IPI-145-07 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymph oma (DUO) III
IRFMN-EN-75 56 (AtTEnd) PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER. III
ISG-GEIS 10-0 1(GEIS 25 ) SARCOMAS DE PARTES BLANDAS LOCALIZADOS DE ALTO RIESGO DE EXTREMIDADES Y PARED DE TRONCO EN ADULTOS:
UN ENFOQUE INTEGRADOR QUE INCLUYE QUIMIOTERAPIA ESTÁNDAR VS HISTOTIPO-DIRIGIDA NEOADYUVANTE.
III
ISO-CC-007 A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouraci l, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer. III
ITM-LET-01 (C OMPETE) A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Ther apy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). III
KCP-330-020 "A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS
PLACEBO IN PATIENTS WITH ADVANCED UNRESE CTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)"
III
LINC BR.31 Ensayo Clínico Fase III, prospectivo, aleatorizado, doble ciego, de quimioterapia adyuvante con MEDI4736 versus placebo en pacientes con cáncer de pulmón no microcítico con resección completa III
LPS14201(CA RD) A randomized, open label, multicenter study of Cabazitaxel versus an ARtargeted agent (abiraterone or enzalutamide) in mCRPC patients previously t reated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD) III
M13-694 Estudio de fase 3, controlado con placebo, de carboplatino/paclitaxel con o sin tratamiento concomitante y seguidamente de mantenimiento de velip arib (un inhibidor de la PARP) en pacientes con carcinoma epitelial seroso de ovario, tubárico o peritoneal primario de alto grado en estadio III o IV no tratado previamente. III
MK-7902-010 A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010). III
MO17747-EO RTC 10041(MINDACT) "Ensayo fase III (El uso de microarray en la enfermedad con ganglios negativos y de 1 a 3 ganglios positivos puede evitar la quimioterapia): Estudio pr ospectivo, aleatorizado que compara la firma de 70 genes con los criterios clínico-patológicos comúnmente utilizados, en la selección de pacientes con cáncer de mama de 0 a 3 ganglios positivos para quimioterapia adyuvante" III
MO29406 A SINGLE-ARM OPEN-LABEL MULTI-CENTRE EXTENSION STUDY OF PERTUZUMAB ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OT HER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A HOFFMANN-LA ROCHE-SPONSORED PERTUZUMAB STUDY III
MO29983 (SA UL) AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-URO THELIAL CARCINOMA OF THE URINARY TRACT. III
MO39129 A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHI LIA A PATIENTS WITH INHIBITORS III
MO39193 (IM PASSION) A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CH EMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT
(INOPERABLE LOCALLY ADVANCED OR METASTATIC) TRIPLE-NEGATIVE BREAST CANCER.
III
MS200647-00 05 A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemo radiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer. III
NuTide:121 A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer. III
ODO-TE-B301 (CONTESSA) A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus
Capecitabine Alone in Women wit h HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane.
III
OP-103 (OCE AN) A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients wit h Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide III
OSE2101C301 (ATALANTE 1) "A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinum-based chemotherapy failure or as 3rd line after platinum-fail ure and checkpoint inhibitor-failure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer" III
PCI-32765CA N3001 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study. III
PCYC-1141-C A (PERSPECTIVE) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma III
PENELOPE B Estudio fase III que evalúa palbociclib (PD-0332991), un inhibidor de quinasa dependiente de las ciclinas (CDK) 4/6,
en pacientes con cáncer de mama primario con receptores hormonales positivos y HER2 normal y alto riesgo de recidiva
tras quimioterapia neoadyuvante “PENELOPE B”.
III
PETACC 08 Adjuvant treatment of fully resected stage III colon cancer with FOLFOX-4 versus FOLFOX-4 plus cetuximab III
Pevonedistat- 3001 A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatmen t for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia III
PM1183-C-00 3-14 (ATLANTIS) Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristin e (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinumcontaining Line (ATLANTIS Trial). III
POL6326-009 An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in P atients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer. III
Ponatinib-30 01 Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Ch emotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL) III
PP06489 (POL AR A) A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and
Oxaliplatin) to prevent che motherapy induced peripheral neuropathy (CIPN) in the adjuvant treatment of patients with Stage III or high-risk Stage II colorectal cancer.
III
PP06490 (POL AR M) A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and
Oxaliplatin) to prevent che motherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic
colorectal cancer.
III
PR-30-5017-C (PRIMA) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Adv anced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy III
PRAN-16-52 A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED STUDY OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN PATIENTS ≥18 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD INDUCTION CHEMOTHERAPY III
QBGJ398-301 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in
Subjects With Advanced/ Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial.
III
R2810-ONC-1 676/GOG-3016 (CVP1601) AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF NVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURREN T OR METASTATIC PLATINUMREFRACTORY CERVICAL CARCINOMA. III
R2810-ONC-1 788 A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma. III
RAPIDO RAPIDO " Estudio aleatorizado multicéntrico en fase III de radioterapia de corta duración seguida de quimioterapia preoperatoria de larga duración y cirugía en el cáncer rectal primario de alto riesgo en comparación con quimiorradioterapia convencional y cirugía y óptima quimioterapia adyuvante. III
RG-11-152 (E URO EWING 2012) International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours III
RV-FOL-GELA RC-0683 (Relevance) A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemother apy followed by rituximab in subjects with previously untreated follicular lymphoma. III
SCOT SHORT COURSE ONCOLOGY THERAPY - A STUDY OF ADJUVANT CHEMOTHERAPY IN COLORECTAL CANCER III
SGI-110-07 A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndrom es (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating gents III
SHP620-302 ( AURORA) A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients III
TAK-788-3001 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemothera py in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations. III
TRIANGLE Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma –
a randomized European mcl network trial
III
TS-102(EPOC H) A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemothera py . III
TTD-18-01 (C R- SEQUENCE) Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1 ) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in ntreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CRSEQUENCE. III
WO29636 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERA PY IN PATIENTS WITH PD-L1−SELECTED, HIGH-RISK MUSCLE- NVASIVE BLADDER CANCER AFTER CYSTECTOMY. III
WO29637 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (Antiƒ{PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB I N PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. III
WO30070 A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINAT ION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY . III
WO39210 A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY. III
WO41554 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING
THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS
PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
III
XL184-308 (M ETEOR) Estudio en fase 3, aleatorizado y controlado de Cabozantinib (XL184) frente a Everolimus en sujetos con carcinoma metastásico de células renales que ha progresado después del tratamiento previo con un inhibidor de la tirosina cinasa VEGFR III
XL184-401(EX AMINER) A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared
to 140 mg/Day in Progressive , Metastatic Medullary Thyroid Cancer Patients.
III
PCI-32765FLR 3001 (SELENE) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with E ither Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects with Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) III
GO28667 (M URANO) A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EV ALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB III
CAAA601A22 301 (NETTER-2) A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with
Grade 2 and Grade 3 advance d GEP-NET.
III
J2G-MC-JZJB A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progr essive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer LIBRETTO-531). III
FGCL-3019-08 7 A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatm ent in Patients with Locally Advanced, Unresectable Pancreatic Cancer. III
ATA129-EBV- 302 (TABELECLEUCEL) Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymp hoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study). III
207499 (DRE AMM 8) A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalido mide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone
(PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8).
III
NSABP B-59/ GBG 96 (GeparDouze) A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Bre ast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo. III
D3615C00001 (CAPITELLO-291) A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or
After Treatment with an Aromatase Inhibitor (CAPItello-291).
III
AGO-OVAR 2. 29 /ENGOT OV-34 /GEICO 65-O Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomiz ed Phase III trial . III
MK-6482-005 An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed Af ter Prior PD- 1/L1 and VEGF-Targeted Therapies. III
GO41717 A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION
WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER.
III
M13-494 A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Sub jects with t(11;14) Positive Relapsed or Refractory Multiple Myeloma III
BAY 94-9027/ 19764 (JIVI) Post marketing investigation (PMI) to assess safety and efficacy of JIVI (BAY 94-9027) treatment in patients with hemophilia A III
DS8201-A-U3 01 A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugat e, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic
breast cancer subjects previously treated with T-DM1.
III
MK-3475-A18 A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11). III
MK-7339-012 A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with
Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC).
III
SGNTUC-016 Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresect able locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02). III
D-US-60010-0 01 An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel p lus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas. III
SGN22E-003 ( EV-302) An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, ver sus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. III
M15-954 A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagn osed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS). III
CIBI308A301 (ORIENT-15) A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chem otherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic
Esophageal Squamous Cell Carcinoma (ORIENT-15).
III
IMGN853-041 7 (SORAYA) SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tub e Cancers with High Folate Receptor-Alpha Expression. III
CA209-914 A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Loca lized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. III
QBGJ398-302 (PROOF302) Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothel ial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302). III
MK-3475-671 A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC). III
BLU-667-2303 (AcceleRET) A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non- Smal l Cell Lung Cancer. III
GO41892 (CO NTACT 01) A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATE ZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTI-PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY. III
CL3-95005-00 7 (SUNLIGHT) An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in p atients with refractory metastatic colorectal cancer. III
D910LC00001 (MERMAID-1) A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1). III
2019-013-GL OB1 (FRESCO-2) A GLOBAL, MULTICENTER, RANDOMIZED, PLACEBOCONTROLLED
PHASE 3 TRIAL TO COMPARE THE EFFICACY AND
SAFETY OF FRUQUINTINIB PLUS BES T SUPPORTIVE CARE TO
PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH
REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2).
III
20190009 A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Local ly Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C. III
GCT3013-05 A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lympho ma III
MK-7339-013 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Thera py Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC). III
XL184-315 (C ONTACT-02) A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer. III
HR-BLTN-III-N SCLC A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squam ous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy. III
D9670C00001 (Destiny06) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06). III
73841937NSC 3003 A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in P atients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(MARIPOSA). III
YO42137 (SK YSCRAPER) A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIB ODY) IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA. III
20-214-29/CA 045-022 A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12). III
209227 (INDU CE 4) A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy vers us Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy or First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. III
BO41843 A PHASE III RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COM BINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER. III
ABCSG 50 BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the
Preventive Effect of Denosuma b on Breast Cancer in Women carrying a BRCA1 Germline Mutation.
III
MK-3475-756 A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endoc rine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756) . III
MK-3475-913 A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Ad vanced Merkel Cell Carcinoma (KEYNOTE-913). III
MK-3475-630 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery a nd Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma(LA cSCC) (KEYNOTE-630).. III
MK-7902-008 A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (anti-PD-1/PD-L1 inhibitor) (LEAP-008). III
XL184-311(C OSMIC) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyro id Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy. III
MK-7339-010 A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants wit h Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010). III
CA045009 A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participa nts with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible. III
MK-3475-867 A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or witho ut Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non
Small Cell Lung Cancer (NSCLC) (KEYNOTE-867).
III
CCTL019H230 1 (BELINDA) Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open l abel, phase III trial (BELINDA) III
XL184-313 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab
versus Nivolumab and Ipilim umab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of
Intermediate or Poor Risk.
III
MK-3475-966 A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line The rapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma. III
MM-398-01-0 3-04-III (RESILIENT) RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung C ancer Who Have Progressed on or after Platinum-based First-Line Therapy. III
MK-3475-669 (INCB024360-304) A Phase 3 Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of Pembrolizumab plus Epacadostat versus the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell arcinoma (KEYNOTE- 669/ECHO-304). III
MK-3475-598 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Me tastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598) . III
MK-3475-689 (SCH 9000475) A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuva nt Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC). III
MK-3475-775 /E7080-G000-309 “Ensayo de fase 3, abierto, multicéntrico y aleatorizado para comparar la eficacia y la seguridad de lenvatinib en combinación con pembrolizumab fre nte al tratamiento de elección del médico en pacientes con cáncer de endometrio avanzado” III
MK-3475-789 A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGF R-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) participants
(KEYNOTE-789).
III
KCP-330-023 A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (SVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) III
MK-3475-716 Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716). III
MK-3475-811 Ensayo de fase III, aleatorizado y doble ciego para comparar trastuzumab más quimioterapia y pembrolizumab con trastuzumab más quimioterapia y placebo como tratamiento de primera línea en participantes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado con HER2 positivo (KEYNOTE 811). III
MK-3475-859 A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line tr eatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859). III
MK-3475-412 A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412). III
MK-3475-604 A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475) in combination with Etoposide/Platinum (Cisplatin or Ca rboplatin) for the first-line treatment of Subjects with Extensive Stage Small Cell Lung Cancer (KEYNOTE-604) III
MK-3475-522 "Estudio de fase III, aleatorizado y doble ciego para evaluar pembrolizumab más quimioterapia frente a un placebo más quimioterapia como tratamie nto neoadyuvante y pembrolizumab frente a un placebo como tratamiento adyuvante para el cáncer de mama triple negativo (CMTN)" III
MK-3475-590 "Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo, de Pembrolizumab (MK-3475) en combinación con cisplatino y 5-fluoro uracilo frente a un placebo en combinación con cisplatino y 5-fluorouracilo como tratamiento de primera línea en sujetos con carcinoma esofágico avanzado/metastásico (KEYNOTE-590)" III
MK-3475-119 A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician?s Choice for Metastatic Tr iple Negative Breast Cancer (mTNBC) ? (KEYNOTE-119) III
SSGXXII (GEIS 42) Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study III
MK-3475-189 A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metast atic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189). III
MK-3475-177 (KEYNOTE) A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Sta ge IV Colorectal Carcinoma (KEYNOTE-177). III
MK-3475-091 (PEARLS) Ensayo de fase III, aleatorizado, con el anticuerpo monoclonal anti-PD-1 pembrolizumab (MK-3475) en comparación con placebo en pacientes con CP NM en estadios iniciales tras la resección y la finalización del tratamiento adyuvante de referencia (PEARLS) III
MK-3475-407 A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in Fir st Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407) III
MK-3475-355 (KEYNOTE-355) A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreate d Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer ? (KEYNOTE-355) III
MK-3475-426 Estudio de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con axitinib frente a su nitinib en monoterapia como tratamiento de primera línea del carcinoma renal metastásico (CRm) o localmente avanzado (KEYNOTE-426) III
MK-3475-361 "Ensayo clínico de fase III, aleatorizado y controlado de pembrolizumab con o sin poliquimioterapia a base de platino en comparación con quimiotera pia en sujetos con carcinoma urotelial avanzado o metastásico" III
ALX0681-C30 2 (Post Hercules) Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizuma b (Post-HERCULES). III
MK-3475-061 Ensayo clínico de fase III, aleatorizado y abierto de pembrolizumab (MK-3475) frente a paclitaxel en sujetos con adenocarcinoma gástrico o de la unió n gastroesofágica avanzado que han presentado progresión después del tratamiento de primera línea con platino y fluoropirimidinas. III
MK-3475-048 Ensayo Clínico Fase 3 de Pembrolizumab (MK-3475) en Primera Línea de Tratamiento para Carcinoma Recurrente/Metastásico de Células Escamosas de Cabeza y Cuello III
MK-3475-062 A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination w ith Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. III
MK-3475-024 Ensayo de fase III, abierto y aleatorizado de MK-3475 en comparación con quimioterapia basada en el platino en sujetos tratados en primera línea co n cáncer de pulmón no microcítico metastásico con expresión intensa de PD-L1 III
20180293 A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Gastric Cancer. IV
40KA98 UVEA Use Via Expanded Access to Brigatinib. IV
9785-CL-0123 A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study. IV
AG348-C008 AG348-C008 IV
AIE-ART-2016 -01 (vertex 2.0) Estudio retrospectivo para evaluar el uso de agonistas de los receptores de trombopoyetina en pacientes adultos con trombocitopenia inmune prima ria en España IV
ART-CAB-201 3-01(CATS) Efficacy of Cabazitaxel, Abiraterone and doceTaxel Sequence in men with metastatic castration-resistant prostate cancer: a European, retrospective, observational study (CATS). IV
ATA129-RS00 2 A Retrospective Study of Treatment Outcomes in Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder after He matopoietic Cell Transplant or Solid Organ Transplant who have Failed Rituximab or Rituximab Plus Chemotherapy. IV
B1871039 A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF®) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LE UKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS IV
BAX-OCT-201 1-01/061001 (AHEAD) ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM). IV
BAY 88-8223/ 16996 A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride. IV
BAY-FAC-201 7-01 Estudio de fase IV multinacional para evaluar el patrón de tratamiento en la “vida real” en pacientes con hemofilia A tratados previamente que recib en KOVALTRY (octocog alfa) para la profilaxis habitual. IV
BIG 14-01 (A URORA) AURORA: Investigación de las alteraciones moleculares en el cáncer de mama metastásico. IV
BO39633 AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/O R F. HOFFMANN-LA ROCHE LTD-SPONSORED. TEZOLIZUMAB STUDY IV
C13-1 (S-AVA NT) Follow-up to the AVANT study up to 8 and 10 years (median follow-up) in patients with colon carcinoma. IV
C25006 Estudio de fase 4, abierto, con un único grupo de tratamiento, para evaluar brentuximab vedotin en pacientes con linfoma anaplásico sistémico de cé lulas grandes en recaída o refractario IV
CC-5013-MDS -010 (216900) (Kaleidoscope) A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide IV
CDRB436X2X 02B An open label, multi-center roll-over study to assess longterm safety in patients who are ongoing or have completed
a prior global Novartis or GSK sp onsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment.
IV
CEL-MIE-2012 -01 Estudio observacional post-autorización para evaluar la respuesta de la función renal al tratamiento de pacients con mieloma múltiple en recaída y co n aclaramiento de creatinina IV
CEL-MIE-2012 -02 "Registro observacional post-autorización para evaluar el impacto clínico del inicio de la terapia antitumoral de rescate en pacientes con mieloma mú ltiple (MM) en recaída biológica asintomática frente al inicio del tratamiento en el momento de la recaída sintomática. (Estudio EPA-MMBR) IV
CEL-MIE-2016 -01 Estudio observacional para valorar la carga de la enfermedad, en
términos de Calidad de Vida Relacionada con la Salud y costes
sanitarios directos, e n pacientes con Mieloma Múltiple de nuevo
diagnóstico no candidatos a trasplante autólogo de progenitores
hematopoyéticos en España
Estudio QoLMMBuS.
IV
CEL-SMD-201 2-01 (erasme) "Estudio observacionla post-autorización para evaluar la evolución en la práctica clínica habitual de pacientes recién diagnosticados de síndrome miel odisplásico (SMD) o leucemia mielomonocítica crónica (LMMC), en función del momento de inicio de tratamiento activo. Estudio ERASME IV
CLDK378A2X 01B Estudio de extensión de fase IV, multicéntrico, abierto en pacientes con tumores malignos ALK positivo que hayan finalizado un estudio previo de ceri tinib (LDK378) patrocinado por Novartis y que vayan a beneficiarse del tratamiento continuado con ceritinib según el criterio del investigador. IV
CNIO-CP-02-2 014(PROSTAC) Estudio prospectivo multicéntrico de factores pronósticos en cáncer dePRÓStata resistente a la castración tratados con doceTaxel o Cabazitaxel IV
CNIO-CP-03-2 014(PROSABI) Estudio prospectivo multicéntrico de factores pronósticos en cáncer de PRÓStata resistente a la castración tratados con ABIraterona. IV
CPDR001X2X 01B An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who
have participated in a Novartis -sponsored spartalizumab study as single agent or in combination with other study treatments.
IV
D4200C00104 (CAPRELSA) Estudio europeo observacional y prospectivo para evaluar el beneficio/riesgo de vandetanib (CAPRELSA™) 300 mg en
pacientes con cáncer medular d e tiroides (CMT) sintomático, agresivo, esporádico, localmente avanzado o metastásico, no
resecable, con o sin mutación del RET.
IV
DNO-IBR-201 8-01 Virología e inmunología de la infección por el citomegalovirus (CMV) en el paciente con neoplasias hematológicas en la era
de las nuevas bioterapias.
IV
F-FR-60000-0 01 (CASSIOPE) Prospective noninterventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascularendothelial growth f actor (VEGF)-targeted therapy. IV
FMS-ITK-2016 -01 Estudio observacional prospectivo para evaluar la precocidad, estabilidad y profundidad de la respuesta molecular en pacientes recién diagnosticado s de leucemia mieloide crónica en fase crónica (LMC-FC) tratados con inhibidores de la actividad tirosina-quinasa (ITK) como tratamiento de primera línea en la práctica clínica IV
GCP#04.01.02 0/030 (Nicord Seguiment) Long Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells IV
GEICAM 2016 -04 AN OBSERVATIONAL, RETROSPECTIVE STUDY ON THE PROGRESS OF BREAST CANCER CASES IN MALES AND THE ASSESSMENT OF RELAPSE RISK THRO UGH GENE SEQUENCING. IV
GEICO1703 (B ORNEO) Incidence of Somatic and Germline BRCA Mutations in a Spanish Large Clinic-Based Cohort of Patients with non-Mucinous Epithelial Ovarian Cancer w ith Cross-Laboratory Validation of Somatic Technique (BoRNEO) – A GEICO Study. IV
GEIS 44 Identificacion de biomarcadores pronósticos en el osteosarcoma de alto grado. IV
GEIS 45 "Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de KIT en pacientes con tumores del estroma gastrointestinal (GIST) c on respuesta prolongada a Imatinib". IV
GEM-1801/G EM-IPI-2018-01 ESTUDIO OBSERVACIONAL DESCRIPTIVO SOBRE LAS CARACTERÍSTICAS DEL MELANOMA AVANZADO Y METASTÁSICO EN ESPAÑA. IV
GEM-DAR-20 18-01 Treatment with Daratumumab in relapsed / refractory Multiple Myeloma patients in clinical care practice in Catalonia. A retrospective study IV
GEM-MIE-201 4-01 Estudio observacional prospectivo para identificar los aspectos clínicos que conducen a la toma de decisiones terapéuticas en pacientes con mielofibr osis. IV
GENA-25 Uso práctico de concetrados FVIII de Octafarma en paciente con hemofilia A sin tratamiento previo o mínimamente tratados que se incorporan a un t ratamiento clínico rutinario: estudio observacional de la seguridad y eficacia en un entorno real: "Protect Now" IV
G-EVW-ESP-2 019 (FANHDI) Estudio retrospectivo para evaluar la eficacia y seguridad de Fanhdi® (concentrado plasmático de
Factor VIII/FVW) en pacientes con enfermedad de v on Willebrand en España.
IV
IBCSG 48-14/ BIG 8-13 (POSITIVE) IBCSG 48-14/ BIG 8-13 IV
INN-PAC-201 7-01 (BIOPAC) Estudio Observacional Retrospectivo para Identificar Biomarcadores Predictivos de Respuesta a Paclitaxel en Pacientes con Cáncer de Mama Metastá sico. IV
INS-FAN-2017 -01 (IG1403) A post authorization study to asses the safety and efficacy of Fandhi (Double inactivated human anti-hemophilic factor) sin subjects with Von Willebr and disease. IV
IPS-LAN-2018 -01 (PANNET) “Efectividad de la dosis de 120 mg de lanreotida en pacientes con tumores neuroendocrinos pancreáticos (TNEP) localmente avanzados o metastásico s en la práctica clínica habitual” IV
IRONMAN-ES "IRONMAN-ES: Estudio prospectivo observacional de parámetros
clinicos y biomarcadores en cáncer de próstata avanzado en
hospitales de España".
IV
ISG-GEIS-OS- 2 (GEIS 33) Estudio prospectivo observacional de la expresión de ABCB1/P-glicoproteína como factor para la estratificación biológica del osteosarcoma no metast ático de las extremidades. IV
JAN-DAR-201 8-01 Estudio observacional para describir el impacto de las combinaciones de tratamiento con daratumumab frente a otros tratamientos alternativos en p acientes con mieloma múltiple en recaída / refractario (MMRR). Datos de práctica clínica habitual en España. Estudio GeminiS. IV
ML40221 REAL WORLD CLINICAL PRACTICE STUDY TO EVALUATE 2ND LINE TREATMENT DECISION MAKING AS PER STANDARD OF CARE AND BASED ON FOUND ATION MEDICINE® IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ADENOCARCINOMA HISTOLOGY IN SPAINREAL WORLD CLINICAL PRACTICE STUDY TO EVALUATE 2ND LINE TREATMENT DECISION MAKING AS PER STANDARD OF CARE AND BASED ON FOUNDATION MEDICINE® IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ADENOCARCINOMA HISTOLOGY IN SPAIN.
IV
MSD-CMV-20 17-01 ESTUDIO SOBRE LAS COMPLICACIONES CLÍNICAS DIRECTAS E INDIRECTAS DERIVADAS DE LA DETECCIÓN DE LA INFECCIÓN POR CITOMEGALOVIRUS (C MV) EN PACIENTES CON TRASPLANTE ALOGÉNICO DE CÉLULAS PROGENITORAS HEMATOPOYÉTICAS (ALO-TPH). ESTUDIO CMV-ALOTPH IV
OZM-061 (OL ALA) Olala: A Retrospective/Prospective Analysis of Characterization of the Long-term Responders on Olaparib in Solid Tumours. IV
PCYC-1145-LT Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials IV
PFI-ITK-2015- 01/ A6181218 (TROYA) "Estudio observacional, prospectivo y multicéntrico de calidad de vida en relación con la fatiga y el síndrome mano-pie de los pacientes con carcinom a renal metastásico tratados con un inhibidor de la tirosina quinasa en primera línea (Estudio TROYA)". IV
PUMA-NER-9 501 (HER-SEQ) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for Enrollment into Clinical Research Studies of Neratinib. IV
Sobi.Elocta-0 02 (A-SURE) 24-month prospective, multicentre, noninterventional study to evaluate the effectiveness of Elocta compared to
conventional factor products in the prophylactic treatment of patients with haemophilia A (A-SURE).
IV
SOG-PLA-201 6-01 Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progre sión tras quimioterapia basada en platino. IV
SOGUG-2019- 01 SOGUG-2019-IEC(REN)-1 (PROANG) Estudio observacional y retrospectivo, sobre el valor pronóstico de la expresión de PDL1 y otros marcadores moleculares angiogénicos, en pacientes c on carcinoma de células renales (CCR) avanzado o metastásico tratados con fármacos antiangiogénicos en primera línea. IV
VHIO18001 ( DOTATOC) Identificación de los diferentes patrones de captación mediante PET con 18F-FDG y 68Ga-DOTApéptidos en los tumores neuroendocrinos avanzados. IV
D910FC00001 (WAVE) An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durv alumab in Other Protocols (WAVE). IV
ISG -2016-SA CRO (GEIS 54) SAcral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease (SACRO). IV
Sobi.Elocta-0 05 (A-MORE) Estudio observacional, multicéntrico de 48 meses de seguimiento para evaluar la eficacia a largo plazo de Elocta en la salud articular. IV
ML41735 / R OC-TRA-2019-02 (KARMA) RETROSPECTIVE OBSERVATIONAL STUDY TO ASSESS DEMOGRAPHIC AND CLINICOPATHOLOGICAL PROFILE AND MANAGEMENT OF PATIENTS WITH H ER2- POSITIVE EARLY-STAGE BREAST CANCER AND RESIDUAL DISEASE TREATED WITH ADJUVANT TRASTUZUMAB EMTANSINE IN SPAIN: KARMA STUDY. IV
B7461027 Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Pr ogressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI). IV
TTD-20-01
(R ETUD)
Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores
digestivos.
IV
MOR208C213 An observational retrospective cohort study of systemic therapies for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), to compare o utcomes to those from Tafasitamab + Lenalidomide in the L-MIND study IV
2018-8023 / L IL-ABE-2019-01 Observational study in HR+/Her2- metastatic breast cancer (mBC) patients treated with Abemaciclib in Spain in the Named Patient Use (NPU) Progra m – AbemusS Study. IV
BAY1841788/ 20321 An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-spo nsored studies. IV
CEL-BEN-2019 -01 Real-world trends in clinical management of Relapsed/Refractory Multiple Myeloma (RRMM) patients who have received at least 2 prior anti-myelo ma regimens: results from exploring electronic health records (EHR) with artificial intelligence (AI) – ‘’MYHRAI study’’ IV
KTE-iNHL-RW 2020 Real-World Response/Survival and Treatment Patterns among Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in USA, UK, Franc e, and Spain Oncology Practices. IV
ML40944 (HE MOLIFE) ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA CALIDAD DE VIDA DE PACIENTES CON HEMOFILIA A SIN INHIBIDORES. IV
TAK620-5002 “Multinational CMV Outcomes, Treatment Patterns and Healthcare Resource Utilization Study (OTUS) following hematopoietic Stem Cell Transplant ( HSCT)”. IV
BAY-DAM-20 19-01 (HEM-POWR) HEM-POWR: Estudio observacional para evaluar la eficacia y la seguridad del tratamiento con damoctocog alfa pegol en
la vida real en pacientes con hemofilia A tratados previamente.
IV
SOGUG-2017- A-IEC REN-7 /SOG-CAB-2019-02 (SRWEC) RETROSPECTIVE STUDY OF CABOZANTINIB IN PATIENTS WITH METASTIC OR UNRESECTABLE RENAL CELL CARCINOMA (RCC) IN SPAIN.
SRWEC STUDY ( SPANISH REAL WORLD EVIDENCECABOZANTINIB).
IV
MK-3475-587 A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Curren tly on Treatment or in Follow-up in a Pembrolizumab Trial. IV
REVOLUTION Nivolumab in mRCC patients: Treg function, T-cell Access and NK interactions to predict and improve efficacy. IV
CC-4047-MM- 015 (ARTIMIDS) A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have R eceived at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy IV

Early Clinical Drug Development

Code Clinical Trial Title Phase
1315.2 Combination of Talimogene Laherparepvec with Atezolizumab in residual breast cancer following standard neoadjuvant multi-agent chemotherapy (PROMETEO TRIAL). 0
1336-0011 A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women with Hormone Receptor-Positive and HER2-negative Breast Cancer. 0
1280.18 An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combinatio n with endocrine therapy in patients with locally
advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.
I
1401-0001 An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine in patients with acute myeloid leukemia I
1412-0001 An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability,
pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
I
1426-0001 An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours. I
17-BI-1206-02 A first-in-human phase Ia/b, open label, multicentre, dose escalation study of BI 905711 in patients with advanced gastrointestinal cancers. I
20140318 Phase I, first in human trial evaluating BI 1387446 alone and in combination with BI 754091 in solid tumors. I
20180290 Ensayo clínico de fase I/IIa de BI-1206, un anticuerpo monoclonal contra CD32b
(Fc γ RIIB), en combinación con rituximab en personas con linfoma no hodgkiniano
de linfocitos B de escasa malignidad que ha recidivado o es resistente al rituximab
I
2018-523-00US1 A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318). I
201973 A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects with MUC17-Positive Gastric and Gastroesophageal Junction Cancer. I
204686 A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma. I
204691( ICOS ) A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer. I
204697 "A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors" I
207675 A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects
with Selected Advanced Solid Tumors.
I
208471 A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with ca strate-resistant prostate cancer (CRPC). I
2102-ONC-102 A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL. I
2SMALL A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A 2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer. I
4010-01-001 A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation. I
5225101 (GATTO) Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy. I
56021927PCR2032 (KRONOS) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors I
61186372EDI1001 "A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients with EGFR-Positive Metastatic Solid Tumors" I
63709178AML1001 An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-esistant Prostate Cancer. I
63723283LUC1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer. I
64091742PCR2002 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects with Relapsed or Refractory AML. I
64619178EDI1001 A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers. I
67571244AML1001 A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer. I
67856633LYM1001 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
73841937NSC2001 A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). I
8374-CL-0101 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL I
A206T-G01-001 (PROTER) A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC). I
ACT15320 A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
ACT15377 A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) p ositive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic
treatment.
I
AFM24-101 A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma I
AG270-C-001 Estudio en fase 1/2, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de isatuximab (SAR650984) en combinación con atezolizumab o solo isatuximab en pacientes con enfermedades malignas avanzadas I
AMC303-01 A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers. I
ARMY-1 A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP. I
ARRAY-162-202 "A safety, tolerability and pharmacokinetic dose escalation and expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin?" I
ARTFORCE First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia I
AUTO4-TL1 An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation I
B7461001 Cisplatin concomitant with standard or adaptive high dose radiotherapy for advanced head and neck cancer. I
B9991005 A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMENT TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR
REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA.
I
B9991023 PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS. I
B9991032 A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WIT H ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. I
BAY 1163877 / 19131 A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREAT MENT IN PATIENTS WITH ADVANCED MALIGNANCIES. I
BAY 1163877/19774 (ROCOCO) A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS. I
BAY88-8223/19781 An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. I
BAY94-9343/15834 A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose (RP2D)of the combination of rogaratinib and copanlisib in patients with FGFR-positive refractory, locally advanced or metastatic s olid tumors. I
BGB-290-103 An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer. I
BGB-A317/BGB-290 Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies. I
BLU-285-1101 A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors. I
BLU-554-1101 A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety,
Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in Combination with the PARP Inhibitor BGB-290 i n Subjects with Advanced Solid Tumors.
I
BLU-667-1101 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors. I
BO39610 A Phase 1 Study to Assess the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma
I
BO40933 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. I
BP39365 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MORPHEUS-LUNG). I
BP40087 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB IN COMBINATION WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN, OR PROSTATE CANCER. I
BP40234 AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, DOSE-ESCALATION, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6874281, IN COMBINATION WITH ATEZOLIZUMAB ±
BEVACIZUMAB, FOLLOWING OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH UNRESECTABLE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.
I
BP40657 AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7122290, A FIBROBLAST ACTIVATION
PROTEIN-a (FAP) TARGETED 4-1BB LIGAN D (CD137L), WITH OR WITHOUT OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB FOLLOWED BY TUMOR SPECIFIC EXPANSION COHORT(S).
I
BP41054 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMB INATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
BP41072 A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY TREAT ED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. I
BREPEM-LH-22017 AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED AND/OR METASTATIC MELANOMA. I
Brigatinib-1001 AN OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7227166 (A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH BINUTUZUMAB AND IN COMBINATION WITH R O7082859 (CD20-TCB) FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S
LYMPHOMA.
I
C0541001 "A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Lymphoma (HL)". I
C2321001 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. I
CA001044 A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS. I
CA011-001 A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FO LLICULAR LYMPHOMA (FL). I
CA017-003-II A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer I
CA022-001 A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors or Hematologic Mallign ancies. I
CA209-358 A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors. I
CA209-848 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. I
CA223-001 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors. I
CA224-020 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H). I
CADPT01A12101C "A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors" I
CB103-C-101 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-9 36558) in Advanced Solid Tumors I
CC-122-DLBCL-002 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer. I
CC-122-ST-001 A PHASE I/IIA, MULTI-CENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY WITH EXPANSION ARMS TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CB-103 ADMINISTERED ORALLY IN ADULT PATIENTS WIT H ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL ALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY . I
CC-220-MM-001 A Phase 1/2 Open-label, Multicenter Study of CC-122 in Combination With R-CHOP-21 for Previously Untreated Poor-Risk (IPI ≥ 3) Diffuse Large B-Cell Lymphoma I
CC-90002-ST-001 Estudio de fase 1a/1b multicéntrico, abierto, de búsqueda de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia preliminar del modificador de la ruta pleiotrópica, CC-122, administrado por vía oral a sujetos con tumores sólid os avanzados, linfoma no Hodgkin o mieloma múltiple I
CC-90010-ST-001 A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY AND I N COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA I
CC-90011-SCLC-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-90002, A MONOCLONAL ANTIBODY DIRECTED AGAINST CD47, IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS I
CC-90011-ST-001 A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90010 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY NON-HODGKIN?S LYMPHOMAS I
CC-99282-CLL-001 A PHASE 1B, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-90011 GIVEN IN COMBINATION WITH CISPLATIN AND ETOPOSIDE TO SUBJECTS WITH FIRST LINE, EXTENSIV E STAGE SMALL CELL LUNG CANCER. I
CC-99282-NHL-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90011 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN’S LY MPHOMAS. I
CDRB436C2201-MEK116833 A PHASE 1B, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-99282 IN COMBINATION WITH OBINUTUZUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMP HOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. I
CFAZ053X2101 A PHASE I, MULTI-CENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND
PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH RITUXIMAB IN SUBJECTS WIT H RELAPSED OR REFRACTORY NONHODGKIN LYMPHOMAS (R/R NHL)
I
CGWN323X2101 An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical
Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in
Combin ation in Subjects with BRAF-mutation V600E or V600K Positive Colorectal Cancer.
I
CHDM201X2101 A phase I, open-label, multi-center dose escalation study of FAZ053 as single agent and in combination with PDR001 in
adult patients with advanced malignancies.
I
CHDM201X2103C A Phase I/Ib open-label, multi-center, dose escalation study of GWN323 (anti-GITR) as a single agent and in combination with PDR001 (anti-PD-1) in patients with advanced solid tumors and lymphomas I
CIDH305X2101 A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and
hematological tumors characterized by wild-type TP53 .
I
CINC280X2105C A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma I
CJBH492A12101 A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations. I
CKAZ954A12101 A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR
mutated non-small cell lung cancer
I
CLAG525X2101C A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL). I
CLAG525X2101C-II A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors. I
CLDK378A2120C A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies I
CLEE011X2106 A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies. I
CLGK974X2101 A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) I
CLHC165X2101 A phase Ib/II trial of LEE011 in combination with everolimus (RADO001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive, Her2 negative locally advanced or metastatic breast cancer. I
CLXH254X2101 A Phase I, open-label, dose escalation study of oral LGK974 in patients with melanoma and breast cancer. I
CLXH254X2102 A Phase I/Ib, open-label, multi-center dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 in patients with advanced malignancies. I
CMBG453D12101 A phase I dose finding study of oral LXH254 in adult patients with advanced solid tumors harboring MAPK pathway alterations. I
CNIR178X2201 A Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or
metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma.
I
CNIZ985B12101 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis. I
CNTO1959COR1001 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma. I
CO40115 A Phase I/Ib Study of Subcutaneous Recombinant NIZ985 ((het-IL-15) (IL-15/sIL-15Rα)) in combination with Spartalizumab in adults with check point inhibitor (CPI) relapsed advanced malignancies. I
CO40939 A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the
Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis.
I
CO41012 "A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAS T CANCER (MORPHEUS TNBC)" I
CPDR001C2101 A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUS LY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
CPDR001X2101-II AA PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER. I
CPDR001X2102 Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1unselected, metastatic NSCLC patients I
CP-MGA012-01 Estudio de fase I/II, abierto, multicéntrico, de la eficacia y la seguridad de PDR001 administrado en pacientes con tumores malignos avanzados. I
CP-MGD013-01 Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001
in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) .
I
CTMT212X2106 A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors. I
CTNO155B12101 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms. I
CTNO155X2101 A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors. I
CV-8102-008 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155
in combination with spartalizumab or ribociclib in selected malignancies.
I
D081EC00001 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors I
D2615C00001(BISCAY) Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. I
D4190C00010 EEstudio en fase I, abierto, de 2 partes, multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia de olaparib en combinación con carboplatino; Parte A: aumento escalonado de la dosis de olaparib en combinación con carboplatino en pacie ntes con cáncer de mama avanzado HER-2 negativo; seguida de Parte B: fase de expansión de olaparib en combinación con carboplatino para el tratamiento neoadyuvante de pacientes con cáncer de mama avanzado HER-2 negativo que presentan mutaciones BRCA1/2 en la línea germinal. I
D419NC00001 An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) I
D7980C00001 (MEDI5752) A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody)in Subjects with Advanced Solid Tumors I
D8530C00001 A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors. I
Debio 1143-106 A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics
Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors.
I
DEBIO 1347-101 A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast CancerA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Comb ination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer. I
DEBIO1347-201 SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochon drial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. I
DU176b-A-U157 A phase I, gene alteration-based, open label, multicenter study of oral Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes. I
EMR200647-001 (TRAP001) Ensayo "basket" de fase II del paninhibidor del FGFR selectivo por vía oral Debio 1347 en pacientes con tumores sólidos que presentan una fusión de FGFR1, FGFR2 o FGFR3 I
EOGBM1-18 A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NONRANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS I
GCT1021-01 Ensayo de fase I, abierto, con dosis múltiples ascendentes, para investigar la seguridad, tolerabilidad, farmacocinética, y actividad biológica y clínica de MSB0011359C en sujetos con tumores sólidos metastásicos o localmente avanzados y expansi ón a indicaciones seleccionadas I
GCT1029-01 A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma (Rosalie st udy). I
GCT1044-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. I
GCT1046-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors. I
GCT3009-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumours. I
GCT3013-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects
with malignant solid tumors.
I
GEIS 58 (OLATRASTS) “Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A Firstin-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts” I
GO29781 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma I
GO29834 "Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado" I
GO30103 (FELIX) “An open-label, multicenter, phase I/Ib trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with atezolizumab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma a nd chronic lymphocytic leukemia” I
GO39374 A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR I
GO39733 "A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS" I
GO39932 A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS A ND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER
I
GO40554 A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
GO40800 "A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer" I
GO40987 A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN
PATIENTS WITH PREVIOUSLY UN TREATED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE UNABLE TO TOLERATE FULL-DOSE CHEMOTHERAPY.
I
GS-US-352-4365 "A PHASE IB/II STUDY EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY AND EFFICAC Y OF IDASANUTLIN IN THE MAINTENANCE OF FIRST AML COMPLETE REMISSION " I
H3B-6527-G000-101 A PHASE I, MULTICENTER, OPEN-LABEL PREOPERATIVE SHORT-TERM WINDOW STUDY OF GDC-9545 IN POSTMENOPAUSAL WOMEN WITH STAGE I-III OPERABLE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER. I
H9H-MC-JBAH Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) I
H9H-MC-JBEF An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma I
I5B-MC-JGDL Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination with Lomustine in Patients with Recurrent Malignant Glioma I
I5B-MC-JGDP Protocol H9H-MC-JBEF(a) A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor–? Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti –PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non–Small Cell Lung Cancer, Hepatocellular Carcinoma,or Glioblastoma (Phase 2) I
I6F-MC-JJCD A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma I
I8X-MC-JECA A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer I
ICO-VCN-H&N-2018 A Phase 1b Study of LY3039478 in Combination with Other Anticancer Agents in Patients with
Advanced or Metastatic Solid Tumors.
I
IMC-C103C-101 A Phase 1 Study of LY3200882 in Patients with Solid Tumors. I
IMGN853-0402 A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck. I
INCAGN 1876-201 A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer. I
INCB 01158-101 A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in
Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carbopl atin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.
I
INCB 50465-112 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies. I
INCB 54828-207 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with vanced/Metast atic Solid Tumors. I
INCB 59872-103 A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) I
INCB01158-206 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activatin g FGFR Mutations or Translocations (FIGHT-207). I
INCMGA0012-203 An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma. I
IO102-012(KN-764) A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma. I
IOV-COM-202 A Phase 2 Study of INCMGA00012 (PD-1 inhibitor) in Participants With Selected Solid Tumors (PODIUM-203). I
J1F-MC-JZFA An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer. I
J2J-MC-JZLA A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors. I
KO-ERK-001 A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors. I
KO-TIP-001 A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer. I
LOXO-EXT-17005 Un primer ensayo en humanos de fase I de KO-947 en malignidades no hematológicas localmente avanzadas, no reseccionableso metastásicas,
recidivantes y/o refractarias
I
LOXO-RET-17001 An Open Label Phase II Study of Tipifarnib in Advanced NonHematological Malignancies with HRAS Mutations I
LOXO-RET-18037 A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion
Cancers.
I
LOXO-TRK-15002 "A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medularry Thyroid Cancer, and Other Tunors with Increased RET Activity". I
M19-037 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201). I
MCLA128-CL-01 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors I
MCLA-158-CL01 A Phase 1, Multi-Center, Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Pharmacokinetics of ABBV-927 and ABBV-368 with and without ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumor. I
MEN1309-01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors I
MEN1611-01(B PRECISE 01) Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors. I
MO29518 OPEN-LABEL, MULTICENTER, PHASE I DOSE ESCALATION STUDY OF MEN1309, A CD205 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH CD205-POSITIVE METASTATIC SOLID TUMORS AND NON-HODGKIN LYMPHOMA. I
MS100036-0020 OPEN-LABEL, MULTICENTER, PHASE IB DOSE-ESCALATION STUDY OF MEN1611, A PI3K INHIBITOR COMBINED WITH TRASTUZUMAB ± FULVESTRANT, IN SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADV ANCED) OR METASTATIC (A/M) BREAST CANCER PROGRESSED TO ANTI-HER2 BASED THERAPY . I
MSC-1-101 AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMORS I
NP30179 A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the DNA-PK inhibitor M3814 in combination with cap ecitabine and radiotherapy in participants with locally advanced rectal cancer. I
NP39488 “A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients with Advanced Solid Tumors. I
NP40126 A MULTICENTER, OPEN-LABEL, PHASE I STUDYTO EVALUATE THE SAFETY, EFFICACY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERE D AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF OBINUTUZUMAB (GAZYVA/GAZYVARO) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA I
NP40435 AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA I
NP41300 A PHASE 1B STUDY EVALUATING RO7082859 IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH RELAPSED REFRACTORY FO LLICULAR LYMPHOMA (R/R FL) OR IN PARTICIPANTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA I
PCI-32765LYM1002 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7121661, A PD-1/TIM-3 BISPECIFIC NTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
PCYC-1128-CA AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
Pevonedistat-1016 A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies I
PM14-A-001-17 A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors I
PRN1371-001 “A Phase 1/1b Study of Pevonedistat in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myelogenous Leukemia With Severe Renal Impairment or Mild Hepatic I mpairment” I
PUMA NER-5201 Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors I
P-VCNA-001 A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with
Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations
I
R1979-ONC-1504 An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal
Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification.
I
R2810-ONC-1423 (REGENERON) A phase I, multicenter, open-label, dose escalation study of intravenous administration of VCN-01 oncolytic adenovirus with or without gemcitabine and Abraxane® in patients with advanced solid tumors. I
REALIB-LLA-2017 A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, AND REGN2810, AN ANTI-PROGRAMMED DEATH-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH B-CELL MA LIGNANCIES I
RXDX-101-02 (STARTRK-2) A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death – 1
(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies
I
SC103 Ensayo en fase I-II, sin enmascaramiento y no aleatorizado, para evaluar el papel de Idelalisib en pacientes con leucemia linfoblástica aguda (LLA) en recaída o refractarios a otros tratamientos, y en pacientes ancianos con LLA en los que se desaco nseja el uso de terapias convencionales I
SGN228-001 "An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements" I
SGN47M-001 A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. I
SGNTV-001 A phase 1 study of SGN-CD228A in subjects with select advanced solid tumors. I
SL01-DEL-101 A phase 1 study of SGN-CD47M in patients with advanced
solid tumors.
I
SOLTI-1503 (PROMETEO) Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. I
SOLTI-1802 (ONAWA) Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas. I
SRA737-02 Ensayo en fase I/II de SRA737 (un inhibidor de Chk1) administrado por vía oral en combinación con gemcitabina más cisplatino o gemcitabina únicamente en pacientes con cáncer avanzado. I
SYM015-01 Ensayo de fase 1a/2a, abierto y multicéntrico, para investigar la seguridad, tolerabilidad y actividad antitumoral de dosis repetidas de Sym015, una mezcla de anticuerpos monoclonales dirigida frente al receptor MET, en pacientes con tumores ma lignos sólidos en fase avanzada I
TCD14678 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination
with cemi plimab in adult patients with advanced solid tumors.
I
TED13751 A first-in-human study for the evaluation of the safety, pharmacokinetics and antitumor activity of SAR408701 in patients with advanced solid tumors. I
TPU-TAS-120-101 A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR MULTIPLE MYELOMA WITH FGF/FGFR-RELATED ABNORMALITIES I
TRASTS-I (GEIS 37) Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos I
U31402-A-U102 A MULTICENTER, OPEN-LABEL PHASE 1 STUDY OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE NON-SMALL CELL LUNG CANCER.
I
VHIO17002 (MO39164) Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours. I
VHIO-PBF-999-01 "Phase I/Ib trial of single agent PBF-999 in solid tumour advanced cancer" I
W00101 IV 1 01 Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors International, multicenter, open label study. I
WIN001 (SPRING) Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and tra nscriptomics to match patients to the combination. I
WO39409 "A phase Ib combination study of rucaparib (CO-338) and atezolizumab (MPDL3280A) in patients with advanced gynecologic cancers and triple-negative breast cancer" I
WO39608 (MORPHEO 1) A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL AD ENOCARCINOMA (MORPHEUS-PANCREATIC CANCER). I
WO39613 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC). I
WP29945 AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCA LLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS. I
WP41188 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7296682, A CD25-TARGETING, T-REGULATORY CELL DEPLETING A NTIBODY IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS I
WP41377 A FIRST IN HUMAN, OPEN LABEL, DOSE ESCALATION PHASE I STUDY EVALUATING SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ACTIVITY PROFILE OF SINGLE AGENT RO7119929 (TLR7 AGONIST 4 ASIP) ADMINISTERED O RALLY TO PARTICIPANTS WITH UNRESECTABLE ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA, BILIARY TRACT CANCER, OR SOLID TUMORS WITH PREDOMINANTLY HEPATIC METASTASES. I
X16082 Ensayo de fase Ib/II para evaluar la eficacia y seguridad de ixazomib oral en combinación con sirólimus y tacrólimus como profilaxis de la enfermedad injerto contra huésped crónica. I
XL184-021 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
XL184-021 (PULMON) A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
YO39609 "A phase Ib/II, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesoph ageal junction cancer (morpheus-gastric cancer) " I
YO40482 A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER. I
ZEN003694-004 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer. I
MS201922-0001 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors. I
42756493CAN2002/ODIN (RAGNAR) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations. I
208850 (STING) A Phase I First Time in Human Open Label Study of GSK3745417 administered with and without Anticancer Agents in Participants with Advanced Solid Tumors. I
B9991040 (JAVELIN IL-2 Medley) Phase 1b/2 clinical trial in patients locally recurrent (not amenable to curative intent) or metastatic SCCHN or metastatic castration-resistant prostate cancer (mCRPC), I
KRT-232-104 "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)" I
SOLTI-1507 (IPATHER) A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PI3KCA-mutant, HER2-positive locally advanced or metastatic breast cancer (IPATHER) I
2455-002 An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma. I
EOADR1-19 (SPENCER) A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromo cytoma/paraganglioma. I
GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS
OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH
TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS.
I
CO41942 ESTUDIO DE FASE IB, SIN ENMASCARAMIENTO, MULTICÉNTRICO, NO ALEATORIZADO, PARA EVALUAR LA SEGURIDAD, LA FARMACOCINÉTICA Y LA EFICACIA DE MOSUNETUZUMAB EN COMBINACIÓN CON LENALIDOMIDA, O RO7082859 EN COMBI NACIÓN CON LENALIDOMIDA, O RO7082859 EN COMBINACIÓN CON OBINUTUZUMAB MÁS LENALIDOMIDA EN PACIENTES CON LINFOMA FOLICULAR RESISTENTE O RECIDIVANT I
CO41863 A PHASE Ib/II, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTANSINE (T-DM1) IN PREVIO USLY TREATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS. I
CC-90010-GBM-002 A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90010 IN COMBINATION WITH TEMOZOLOMIDE
WITH OR WITHOUT RADIATION THERAPY IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.
I
CC-90011-ST-002 A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers. I
BP41628 AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSEESCALATION AND EXTENSION, PHASE IA/IB STUDY TO
EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN C OMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
I
BNT411-01 Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer
(ES-SCLC).
I
CO41792 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. I
ODO-TE-S101 An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food,Itraconazole,and Rifampinon Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors. I
1438-0001 A First–in-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL 3. I
M19-611 A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer. I
4020-01-001 (AMBER) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER). I
WP42004 "ESTUDIO DE FASE I, MULTICÉNTRICO Y ABIERTO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA Y FARMACODINÁMICA DE RO7283420 EN MONOTERAPIA EN LEUCEMIA MIELOIDE AGUDA EN RECAÍDA/RESISTENTE HEMATOL ÓGICA Y MOLECULAR" I
ICT01-101 A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/r efractory cancer (EVICTION Study). I
1381.2 An open label, Phase I dose-finding study of BI 754111 in combination with BI 754091 in patients with advanced solid
cancers followed by expansion cohorts at the selected dose of the combination in patients with non-small cell lung cancer and ot her solid tumors.
I
DCC-3014-01-001 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors. I
D6770C00001 Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumors. I
DEBIO 1143-106-II SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochon drial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. I
70218902EDI1001 A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors. I
Debio 0123-101 A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors. I
20180292 A Global Phase 1 Study Evaluating the Safety,Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. I
CBLZ945X2101 A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors. I
MEN1611-02 (C-PRECISE-01) OPEN-LABEL,MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CAMUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING RE GIMENS. I
CA011-001(HEMATOLOGIA) A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors or Hematologic Maligna ncies I
V937-013 Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors. I
GO41751 A PHASE I, OPEN-LABEL, DOSE-ESCALATION PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER. I
CYTB323A12101 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL. I
CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers. I
SGNTGT-001 A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies. I
73841937NSC1001 An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Part icipants With Advanced Non-Small Cell Lung Cancer. I
213152 A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer with Disease Progression or Recurrence Following Treatment with a Platinun agent. I
CADPT01C12101 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer. I
TAS-120-202 A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations. I
BP42169 AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7293583, A TYRP1-TARGETING CD3 T-CELL ENGAGER, IN PARTICIPANTS WITH METASTATIC MELANOMA. I
DZB-CS-202 (BASILEA) Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03). I
SGNB6A-001 A Phase 1 Study of SGN-B6A in Advanced Solid Tumors. I
MS200647_0046 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer. I
FS222-19101 (F-STAR) A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects with Advanced Malignancies. I
1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit. I
MK-7339-002 A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer. I
NBTXR3-102 ESTUDIO DE FASE I DE AUMENTO ESCALONADO/AMPLIACIÓN DE LA DOSIS DE NBTXR3 ACTIVADO MEDIANTE RADIOTERAPIA DE INTENSIDAD MODULADA EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS LOCALMENTE AVANZADO EN LA CAVIDAD BUCAL O LA OROFARINGE. I
MK-3475-555 (KEYNOTE-555) A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants with Advanced Melanoma (KEYNOTE-555). I
64619178EDI1001-H A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
207497 (DREAMM6) A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bor tezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – (DREAMM 6) I
MM-398-07-02-03 A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma. I
MK-4280-001 "A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors" I
MK-3475-158 Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158) I
3475-028 Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors. I